

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Abacavir Sulfate	Tablets	300 mg	Ziagen 20977	1/28/2009						
Abacavir	Oral Solution	20 mg/mL	Ziagen 20978	12/27/2012						
Abacavir Sulfate, Dolutegravir and Lamivudine	Tablets	600 mg/50 mg/300 mg	Triumeq 205551	8/14/2017						
Abacavir Sulfate and Lamivudine	Tablets	600 mg/300 mg	Epzicom 21652	9/27/2007						
Abacavir Sulfate, Lamivudine and Zidovudine	Tablets	300 mg/150 mg/300 mg	Trizivir 21205	3/22/2011						
Abiraterone Acetate	Tablets	125 mg	Yonsa 210308	7/23/2018	1					3/17/2034
Abiraterone Acetate	Tablets	250 mg	Zytiga 202379	4/28/2015	13	Eligible	6/18/2019	10/31/2018	11/21/2018	8/24/2027
Abiraterone Acetate	Tablets	500 mg	Zytiga 202379	8/23/2017	1					8/24/2027
Acarbose	Tablets	25 mg, 50 mg and 100 mg	Precose 20482	3/22/2005						
Acetylcysteine	Injection	200 mg/mL, 30 mL vials	Acetadote 21539	4/4/2012						
Acetaminophen*	Injection	1000 mg/100 mL (10 mg/mL)	Ofirmev 22450	4/7/2011						
Acetaminophen	Extended-release Tablets	650 mg	Tylenol 19872							
Acetaminophen and Tramadol Hydrochloride	Tablets	325 mg/ 37.5 mg	Ultracet 21123							
Acetaminophen/ Aspirin/ Caffeine	Tablets	250 mg/ 250 mg/ 65 mg	Excedrin (migraine) 20802							
Acyclovir Sodium	Injection	50 mg/mL, 10 mL and 20 mL vials	Zovirax 18603							
Adapalene	Topical Gel	0.30%	Differin 21753	9/15/2009						
Adapalene and Benzoyl Peroxide	Gel	0.1%/2.5%	Epiduo 22320	12/30/2011						
Adapalene and Benzoyl Peroxide	Gel	0.3%/2.5%	Epiduo Forte 207917	5/4/2016	1	Eligible	6/18/2019	10/17/2018		3/12/2023
Adefovir Dipivoxil	Tablets	10 mg	Hepsera 21449	6/8/2010						
Afatinib Dimaleate	Tablets	20 mg, 30 mg and 40 mg	Gilotrif 201292	7/12/2017						
Adenosine	Injection	3 mg/mL, 20 mL and 30 mL vials	Adenoscan 20059	4/16/2005						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Albuterol Sulfate	Oral Syrup	2 mg(base)/ 5 mL	Ventolin 19621							
Albuterol Sulfate	Extended-release Tablets	4 mg and 8 mg	Volmax 19604							
Albuterol Sulfate	Inhalation Solution	0.021% and 0.042%	Accuneb 20949	10/19/2005						
Albuterol Sulfate/ Ipratropium Bromide	Inhalation Solution	0.083%/ 0.017%	Duoneb 20950							
Albuterol Sulfate	Inhalation Aerosol	0.09 mg base per actuation	Pro-Air HFA 21457	5/18/2012						
Albuterol Sulfate	Inhalation Aerosol	0.09 mg base per actuation	Proventil HFA 20503	5/20/2015						
Alcaftadine*	Ophthalmic Solution	0.25%	Lastacaft 22134	7/30/2014	1	Extinguished	8/27/2019			10/5/2029
Alendronate Sodium*	Oral Solution	70 mg/75 mL	Fosamax 21575	9/7/2007						
Alendronate Sodium	Tablets	5 mg, 10 mg, 35 mg, 40 mg and 70 mg	Fosamax 20560							
Alendronate Sodium and Cholecalciferol	Tablets	70 mg/2800 IU and 70 mg/5600 IU	Fosamax Plus D 21762	11/20/2007						
Alfuzosin Hydrochloride	Extended-release Tablets	10 mg	Uroxatral 21287	6/12/2007						
Aliskiren Hemifumarate	Tablets	150 mg and 300 mg	Tekturna 21985	1/27/2014	1	Deferred	8/13/2019	3/22/2019	3/25/2019	2/19/2026
Aliskiren Hemifumarate and Hydrochlorothiazide	Tablets	150 mg/12.5 mg 150 mg/25 mg 300 mg/12.5 mg 300 mg/25 mg	Tekturna HCT 22107	3/7/2014						
Almotriptan Malate	Tablets	6.25 mg and 12.5 mg	Axert 21001	12/8/2005						
Alogliptin	Tablets	6.25 mg, 12.5 mg and 25 mg	Nesina 22271	1/25/2017						
Alogliptin and Metformin Hydrochloride	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg	Kazano 203414	1/25/2017						
Alosetron Hydrochloride	Tablets	0.5 mg and 1 mg	Lotronex 21107	12/2/2010						
Alprazolam	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	Niravam 21726	12/27/2005	1	Extinguished Eligible	7/2/2019 7/2/2019	1/9/2009	1/14/2009	4/9/2018

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Alprazolam	Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	Xanax 18276							
Alvimopan	Capsules	12 mg	Entereg 21775	6/16/2017						
Amantadine	Extended-release Capsules	137 mg	Gocovri 208944	1/16/2018						
Ambrisentan*	Tablets	5 mg and 10 mg	Letairis 22081	2/9/2015	1	Extinguished	8/27/2019	3/28/2019		7/9/2018
Amifostine	For Injection	500 mg/vial	Ethylol 20221	4/16/2004						
Amlodipine Besylate	Tablets	2.5 mg, 5 mg and 10 mg	Norvasc 19787							
Amlodipine Besylate and Atorvastatin Calcium	Tablets	2.5 mg/10 mg 2.5 mg/20 mg 10 mg/40 mg	Caduet 21540	9/17/2009						
Amlodipine Besylate and Atorvastatin Calcium	Tablets	2.5 mg/40 mg	Caduet 21540	9/17/2009						
Amlodipine Besylate and Atorvastatin Calcium*	Tablets	5 mg/10 mg 5 mg/20 mg 5 mg/40 mg 10 mg/10 mg 10 mg/20 mg 10 mg/80 mg	Caduet 21540	12/29/2006						
Amlodipine Besylate and Atorvastatin Calcium	Tablets	5 mg/80 mg	Caduet 21540	4/7/2009						
Amlodipine Besylate and Benazepril Hydrochloride	Capsules	2.5 mg/10 mg 5 mg/10 mg 5 mg/20 mg 10 mg/20 mg	Lotrel 20364	6/9/2004						
Amlodipine Besylate and Benazepril Hydrochloride	Capsules	5 mg/40 mg and 10 mg/40 mg	Lotrel 20364	11/17/2006						
Amlodipine Besylate and Olmesartan Medoxomil	Tablets	5 mg/20 mg and 10 mg/40 mg	Azor 22100	2/11/2008						
Amlodipine Besylate and Olmesartan Medoxomil	Tablets	10 mg/20 mg and 5 mg/40 mg	Azor 22100	3/31/2008						
Amlodipine Besylate and Valsartan	Tablets	5 mg/160 mg	Exforge 21990	10/22/2007						
Amlodipine Besylate and Valsartan	Tablets	5 mg/320 mg	Exforge 21990	11/26/2007						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Amlodipine Besylate and Valsartan	Tablets	10 mg/160 mg	Exforge 21990	10/1/2007						
Amlodipine Besylate and Valsartan	Tablets	10 mg/320 mg	Exforge 21990	11/9/2007						
Amlodipine, Hydrochlorothiazide and Valsartan	Tablets	5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 mg	Exforge HCT 22314	9/14/2009						
Amlodipine, Hydrochlorothiazide and Valsartan	Tablets	10 mg/12.5 mg/160 mg	Exforge HCT 22314	10/22/2009						
Amoxicillin and Clavulanate Potassium	Extended-release Tablets	1000 mg/62.5 mg	Augmentin XR 50785	1/21/2009						
Amphetamine	Extended-release Orally Disintegrating Tablets	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	Adzenys XR-ODT 204326	5/10/2016	1					1/28/2032
Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate	Extended-release Capsules	37.5 mg and 50 mg	Mydayis 22063	8/3/2017						
Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate	Extended-release Capsules	12.5 mg and 25 mg	Mydayis 22063	8/7/2017						
Apixaban	Tablets	2.5 mg and 5 mg	Eliquis 202155	12/28/2016	25					2/24/2031
Apremilast	Tablets	10 mg, 20 mg and 30 mg	Otezla 205437	3/22/2018						
Aprepitant	Capsule	40 mg, 80 mg and 125 mg	Emend 21549	11/3/2008						
Aprepitant	for Oral Suspension	125 mg/Kit	Emend 207865	11/23/2016						
Arformoterol Tartrate *	Inhalation Solution	Eq. 0.015 mg base/2 mL	Brovana 21912	10/1/2009	1	Extinguished	7/2/2019			11/9/2021
Argatroban*	Injection	100 mg/mL, 2.5 mL vials	Argatroban 20883	9/24/2007						
Argatroban in Sodium Chloride*	Injection	1 mg/mL, 50 mL vials	Argatroban 22434	12/16/2011						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Aripiprazole	Oral Solution	1 mg/mL	Abilify 21713	12/20/2007						
Aripiprazole	Tablets	2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	Abilify 21436	11/15/2006						
Aripiprazole	Orally Disintegrating Tablets	10 mg, 15 mg, 20 mg and 30 mg	Abilify 21729	11/15/2006						
Armodafinil	Tablets	50 mg, 150 mg and 250 mg	Nuvigil 21875	7/24/2009						
Armodafinil *	Tablets	100 mg	Nuvigil 21875	9/8/2009						
Armodafinil *	Tablets	200 mg	Nuvigil 21875	9/3/2009						
Arsenic Trioxide	Injection	1 mg/mL	Trisenox 21248	8/11/2015						
Asenapine Maleate	Sublingual Tablets	5 mg and 10 mg	Saphris 22117	8/13/2013						
Asenapine Maleate	Sublingual Tablets	2.5 mg	Saphris 22117	7/27/2017						
Aspirin and Omeprazole *	Delayed-release Tablets	81 mg/40 mg and 325 mg/40 mg	Yosprala 205103	10/14/2016						
Aspirin and Dipyridamole	Extended-release Capsules	25 mg and 200 mg	Aggrenox 20884	2/1/2007						
Atazanavir Sulfate	Capsules	100 mg and 150 mg	Reyataz 21567	3/19/2010						
Atazanavir Sulfate	Capsules	200 mg	Reyataz 21567	2/16/2010						
Atazanavir Sulfate	Capsules	300 mg	Reyataz 21567	7/20/2009						
Atazanavir Sulfate and Cobicistat	Tablets	300 mg/150 mg	Evotaz 206353	9/13/2017						
Atenolol	Tablets	25 mg, 50 mg and 100 mg	Tenormin 18240							
Atenolol/ Chlorthalidone	Tablets	50 mg/25 mg and 100 mg/25 mg	Tenoretic 18760							
Atovaquone*	Oral Suspension	750 mg/5 mL	Mepron 20500	10/20/2009						
Atovaquone and Proguanil Hydrochloride	Tablets	62.5 mg/25 mg	Malarone 21078	9/14/2010						
Atovaquone and Proguanil Hydrochloride	Tablets	250 mg/100 mg	Malarone 21078	4/3/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Atomoxetine Hydrochloride	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	Strattera 21411	5/29/2007						
Atorvastatin Calcium	Tablets	10 mg, 20 mg, 40 mg and 80 mg	Lipitor 20702							
Avanafil	Tablets	50 mg, 100 mg and 200 mg	Stendra 202276	4/27/2016						
Axitinib	Tablets	1 mg and 5 mg	Inlyta 202324	2/23/2018						
Azelaic Acid	Gel	15%	Finacea 21470	7/27/2012						
Azelaic Acid	Topical Foam	15%	Finacea 207071	9/14/2017						
Azelastine Hydrochloride	Nasal Spray	0.125 mg base/spray	Astelin 20114	11/14/2005						
Azelastine Hydrochloride	Nasal Spray	205.5 mcg/spray	Astepro 22203	12/15/2011						
Azelastine Hydrochloride	Ophthalmic Solution	0.05%	Optivar 21127	12/13/2006						
Azelastine Hydrochloride and Fluticasone Propionate	Nasal Spray	137 mcg/50 mcg per spray	Dymista 202236	6/13/2014	1	Eligible	6/18/2019	4/28/2017		8/24/2026
Azithromycin	for Injection	500 mg/vial	Zithromax 20733	6/17/2011						
Azithromycin *	Ophthalmic Solution	1%	Azasite 50810	3/3/2011						
Balsalazide Disodium	Tablets	1.1 g	Giazo 22205	11/5/2013						
Belinostat	Injection	500 mg/vial	Beleodaq 206256	7/3/2018						
Bendamustine Hydrochloride	Injection	25 mg/vial and 100 mg/vial	Treanda 22249	6/4/2013						
Bendamustine Hydrochloride	Injection	90 mg/mL, 0.5 mL and 2 mL in single-dose vials	Treanda 22249	6/19/2014						
Bendamustine Hydrochloride	Injection	100 mg/4 mL (25 mg/mL) multiple-dose vials	Bendeka 208194	5/4/2017						
Bendamustine Hydrochloride	Injection	100 mg/4 mL (25 mg/mL) multiple-dose vials	Bendamustine Hydrochloride Injection 205580	7/17/2018						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Benzyl Alcohol	Lotion	5%	Ulesfia 22129	4/11/2016						
Bepotastine Besilate	Ophthalmic Solution	1.5%	Bepreve 22288	9/9/2013						
Betamethasone Valerate	Foam	0.12%	Luxiq 20934	8/10/2007						
Betamethasone Dipropionate	Topical Spray	0.05%	Sernivo 208079	2/15/2018						
Betaxolol	Ophthalmic Solution	0.5%(base)	Betoptic 19270							
Bexarotene	Capsules	75 mg	Targretin 20155	6/6/2011						
Bimatoprost	Ophthalmic Solution	0.01%	Lumigan 22184	4/5/2011						
Bimatoprost	Ophthalmic Solution	0.03%	Lumigan 21275	12/22/2008						
Bimatoprost	Topical Solution	0.03%	Latisse 22369	5/3/2010	1	Extinguished Deferred	6/18/2019 6/18/2019	12/1/2014		5/25/2024
Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride	Capsules	140 mg/125 mg/125 mg	Pylera 50786	8/12/2014						
Bivalirudin	For Injection	250 mg/vial	Angiomax 20873	9/1/2009						
Bosentan	for Oral Suspension	32 mg	Tracleer 209279	2/8/2019						
Bosutinib	Tablets	100 mg and 500 mg	Bosulif 203341	9/6/2016	3					11/23/2026
Bosutinib	Tablets	400 mg	Bosulif 203341	10/25/2018	1					11/23/2026
Brimonidine	Topical Gel	0.33%	Mirvaso 204708	12/15/2014						
Bortezomib*	For Injection	3.5 mg/vial	Velcade 21602	11/20/2008						
Brexipiprazole New	Tablets	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg	Rexulti 205422	7/10/2019						10/12/2032
Brimonidine Tartrate	Ophthalmic Solution	0.1%	Alphagan P 21770	12/20/2006	1					1/28/2022
Brimonidine Tartrate	Ophthalmic Solution	0.15%	Alphagan P 21262	11/03/2006						
Brimonidine Tartrate	Ophthalmic Solution	0.2%	Alphagan 20613							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Brimonidine Tartrate and Timolol Maleate	Ophthalmic Solution	0.2%/0.5%	Combigan 21398	11/21/2008						
Bromfenac Sodium	Ophthalmic Solution	0.07%	Prolensa 203168	7/26/2013						
Bromfenac Sodium	Ophthalmic Solution	0.075%	Bromsite 206911	10/25/2017	1					8/7/2029
Budesonide	Enteric Coated Capsules	3 mg	Entocort EC 21324	2/1/2008						
Budesonide	Nasal Spray	0.032 mg (32 mcg)/spray	Rhinocort 20746	5/14/2007						
Budesonide	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL	Pulmicort Respules 20929	9/15/2005						
Budesonide	Inhalation Suspension	1 mg/2 mL	Pulmicort Respules 20929	5/28/2010						
Budesonide	Extended-release Tablets	9 mg	Uceris 203634	3/11/2013	1	Deferred	6/18/2019	7/3/2018	7/5/2018	6/9/2020
Budesonide and Formoterol Fumarate Dihydrate	Metered Inhalation	80 mcg/4.5 mcg per inhalation and 160 mcg/4.5 mcg per inhalation	Symbicort 21929	6/26/2018						
Buprenorphine and Naloxone	Buccal Film	2.1 mg/0.3 mg and 4.2 mg/0.7 mg	Bunavail 205637	11/23/2016	1					8/20/2032
Buprenorphine and Naloxone	Buccal Film	6.3 mg/1 mg	Bunavail 205637	12/21/2015	1					8/20/2032
Buprenorphine Hydrochloride	Buccal Film	75 mcg and 150 mcg	Belbuca 207932	10/24/2016	1					7/23/2027
Buprenorphine Hydrochloride	Buccal Film	300 mcg, 450 mcg, 600 mcg and 750 mcg	Belbuca 207932	10/4/2016	1					7/23/2027
Buprenorphine Hydrochloride	Buccal Film	900 mcg	Belbuca 207932	9/12/2016	1					7/23/2027
Buprenorphine Hydrochloride and Naloxone Hydrochloride	Sublingual Film	2 mg/0.5 mg* and 8 mg/2 mg	Suboxone 22410	10/15/2012						
Buprenorphine Hydrochloride and Naloxone Hydrochloride*	Sublingual Film	4 mg/1 mg	Suboxone 22410	5/14/2013						
Buprenorphine Hydrochloride and Naloxone Hydrochloride*	Sublingual Film	12 mg/3 mg	Suboxone 22410	5/14/2013						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate	Sublingual Tablets	1.4 mg/0.36 mg and 5.7 mg/1.4 mg	Zubsolv 204242	10/22/2013						
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate	Sublingual Tablets	8.6 mg/2.1 mg and 11.4 mg/2.9 mg	Zubsolv 204242	7/24/2015						
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate	Sublingual Tablets	2.9 mg/7.1 mg	Zubsolv 204242	12/21/2015						
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate	Sublingual Tablets	0.7 mg/0.18 mg	Zubsolv 204242	5/4/2017						
Buprenorphine *	Transdermal System	5 mcg/hr 10 mcg/hr 20 mcg/hr	Butrans 21306	6/6/2013	1	Extinguished	6/18/2019	11/20/2018		9/29/2017
Buprenorphine *	Transdermal System	15 mcg/hr	Butrans 21306	12/16/2013	1	Extinguished	6/18/2019	11/20/2018		9/29/2017
Bupropion Hydrobromide	Extended-release Tablets	174 mg	Aplenzin 22108	9/28/2009						
Bupropion Hydrobromide	Extended-release Tablets	348 mg	Aplenzin 22108	9/24/2009						
Bupropion Hydrobromide	Extended-release Tablets	522 mg	Aplenzin 22108	12/24/2009						
Bupropion Hydrochloride	Extended-release Tablets	100 mg, 150 mg and 200 mg	Wellbutrin SR 20358							
Bupropion Hydrochloride	Extended-release Tablets	150 mg	Zyban 20711							
Bupropion Hydrochloride	Extended-release Tablets	150 mg and 300 mg	Wellbutrin XL 21515	9/21/2004						
Bupropion Hydrochloride	Extended-release Tablets	450 mg	Forfivo XL 22497	2/28/2013						
Bupropion Hydrochloride	Tablets	75 mg and 100 mg	Wellbutrin 18644							
Buspirone Hydrochloride	Tablets	5 mg, 7.5 mg, 10 mg, 15 mg and 30 mg	Buspar 18731							
Busulfan	Injection	6 mg/mL	Busulfex 20954	12/26/2012						
Butoconazole Nitrate	Vaginal Cream	2%	Gynazole-1 200923	12/23/2009						
Butorphanol Tartrate	Nasal Spray	10 mg/mL	Stadol NS 19890							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Cabazitaxel	Injection	60 mg/1.5 mL	Jevtana 201023	6/17/2014	8					12/10/2025
Cabozantinib New	Tablets	20 mg, 40 mg and 60 mg	Cabometyx 208692	8/16/2019	1					7/9/2033
Calcipotriene	Topical Cream	0.005%	Dovonex 20554	12/2/2009						
Calcipotriene	Topical Solution	0.005%	Dovonex 20611	5/19/2006						
Calcipotriene and Betamethasone Dipropionate	Ointment	0.005%/0.064%	Taclonex 21852	3/31/2010						
Calcitonin-Salmon	Nasal Spray	200 IU/spray	Miacalcin 20313							
Calcitonin-Salmon (Recombinant)	Nasal Spray	200 IU/spray	Fortical 21406	3/29/2006						
Calcitriol	Injection	1 mcg/mL and 2 mcg/mL, 1 mL vials	Calcijex 18874							
Calcium Acetate	Capsules	EQ 169 mg calcium	PhosLo 21160	5/31/2005						
Calcium Acetate	Oral Solution	667 mg/5 mL	Phoslyra 22581	12/5/2013						
Calcium Carbonate/ Famotadine/ Magnesium Hydroxide	Chewable Tablets	800 mg/ 10 mg/ 165 mg (OTC)	Pepcid Complete 20958	11/1/2004						
Canagliflozin	Tablets	100 mg and 300 mg	Invokana 204042	3/29/2017						
Canagliflozin and Metformin Hydrochloride	Tablets	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	Invokamet 204353	3/29/2017						
Canagliflozin and Metformin Hydrochloride	Extended-release Tablets	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	Invokamet-XR 205879	11/21/2018						
Candesartan Cilexetil	Tablets	4 mg, 8 mg, 16 mg and 32 mg	Atacand 20838	12/22/2006						
Candesartan Cilexetil and Hydrochlorothiazide	Tablets	16 mg/12.5 mg and 32 mg/12.5 mg	Atacand HCT 21093	6/25/2008						
Candesartan Cilexetil and Hydrochlorothiazide	Tablets	32 mg/25 mg	Atacand HCT 21093	3/6/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Cangrelor	For Injection	50 mg/vial	Kengreal 204958	6/24/2019	2					7/10/2035
Capecitabine	Tablets	150 mg and 500 mg	Xeloda 20896	11/10/2008						
Captopril	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	Capoten 18343							
Carbamazepine	Extended-release Capsules	100 mg and 200 mg	Carbatrol 20712	2/2/2006						
Carbamazepine*	Extended-release Capsules	200 mg and 300 mg	Equetro 21710	8/21/2007						
Carbamazepine*	Extended-release Capsules	100 mg	Equetro 21710	5/23/2014						
Carbamazepine	Extended-release Capsules	300 mg	Carbatrol 20712							
Carbamazepine	Extended-release Tablets	100 mg	Tegretol-XR 20234	12/30/2005						
Carbamazepine	Extended-release Tablets	200 mg and 400 mg	Tegretol-XR 20234							
Carbidopa, Levodopa and Entacapone	Tablets	12.5 mg, 50 mg and 200 mg	Stalevo 50 21485	8/5/2008						
Carbidopa, Levodopa and Entacapone	Tablets	18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg	Stalevo 75 and Stalevo 125 21485	5/19/2009						
Carbidopa, Levodopa and Entacapone	Tablets	25/100/200 mg and 37.5/150/200 mg	Stalevo 100 and Stalevo 150 21485	6/29/2007						
Carbidopa, Levodopa and Entacapone	Tablets	50 mg/200 mg/200 mg	Stalevo 200 21485	8/28/2008						
Carbidopa/ Levodopa	Extended-release Tablets	25 mg/100 mg and 50 mg/200 mg	Sinemet CR 19856							
Carbidopa and Levodopa	Extended-release Capsules	61.25 mg/245 mg	Rytary 203312	6/10/2015	1					12/26/2028
Carbidopa and Levodopa	Extended-release Capsules	23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	Rytary 203312	6/24/2015	1					12/26/2028
Carboplatin	For Injection	50 mg/vial, 150 mg/vial and 450 mg/vial	Paraplatin 19880							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Carboplatin	Injection	50 mg/vial, 150 mg/vial and 450 mg/vial	Paraplatin 20452							
Carfilzomib	For Injection	10 mg/vial	Kyprolis 202714	11/28/2018						
Carfilzomib	For Injection	60 mg/vial	Kyprolis 202714	7/20/2016						
Carfilzomib	For Injection	30 mg/vial	Kyprolis 202714	10/5/2017	1					2/27/2033
Carisoprodol/ Aspirin	Tablets	200 mg/ 325 mg	Soma Compound 12365							
Carisoprodol/ Aspirin/ Codeine	Tablets	200 mg/ 325 mg/ 16 mg	Soma Compound with Codeine 12366							
Carvedilol	Tablets	3.125 mg, 6.25 mg, 12.5 mg and 25 mg	Coreg 20297							
Carvedilol Phosphate	Extended-release Capsules	10 mg and 20 mg	Coreg CR 22012	3/18/2008						
Carvedilol Phosphate	Extended-release Capsules	40 mg	Coreg CR 22012	12/21/2007						
Carvedilol Phosphate	Extended-release Capsules	80 mg	Coreg CR 22012	11/19/2007						
Caspofungin Acetate *	for Injection	50 mg/vial and 70 mg/vial	Cancidas 21227	6/26/2009						
Cefixime	for Oral Suspension	500 mg/5 mL	Suprax 202091	7/22/2014						
Ceftaroline Fosamil	for Injection	400 mg/vial and 600 mg/vial	Teflaro 200327	10/29/2014						
Celecoxib*	Capsules	50 mg	Celebrex 20998	3/21/2008						
Celecoxib	Capsules	100 mg, 200 mg and 400 mg	Celebrex 20998							
Cetirizine Hydrochloride	Syrup	5 mg/5 mL	Zyrtec 20346	3/19/2007						
Cetirizine Hydrochloride	Chewable Tablets	5 mg and 10 mg	Zyrtec 21621	3/25/2005						
Cetirizine Hydrochloride and Pseudoephedrine	Extended-release Tablets	5 mg/120 mg	Zyrtec-D 21150	6/2/2004						
Cevimeline Hydrochloride	Capsules	30 mg	Evoxac 20989	2/27/2009						

**Paragraph IV Patent Certifications
September 23, 2019**

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Chlorhexidine Gluconate	Scrub brush/sponge	4%	Hibiclens 18423							
Chlorpheniramine Polistirex and Hydrocodone Polistirex	Extended-release Capsules	8 mg/10 mg and 4 mg/5 mg	Tussionex 19111	9/10/2004						
Ciclesonide	Nasal Spray	50 mcg	Omnaris 22004	2/13/2012						
Ciclopirox	Gel	0.77%	Loprox 20519	5/10/2006						
Cinacalcet Hydrochloride *	Tablets	30 mg, 60 mg and 90 mg	Sensipar 21688	3/10/2008	1	Extinguished	8/27/2019			12/14/2016
Ciprofloxacin	Oral Suspension	250 mg/5 mL and 500 mg/ 5 mL	Cipro 20780	10/16/2009						
Ciprofloxacin Hydrochloride	Tablets	100 mg, 250 mg, 500 mg and 750 mg	Cipro 19537							
Ciprofloxacin and Dexamethasone	Otic Suspension	0.3%/0.1%	Ciprodex 21537	7/31/2012	1					8/10/2020
Cisatracurium Besylate (multi-dose)	Injection	2 mg/mL, 10 mL vial	Nimbex 20551	8/12/2009						
Cisatracurium Besylate (preserve free)	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	Nimbex 20551	8/4/2009						
Cisplatin	Injection	1 mg/mL, 10 mL, 50 mL, 100 mL and 200 mL vials	Platinol-AQ 18057							
Cisplatin	For Injection	10 mg/vial and 50 mg/vial	Platinol 18057							
Clarithromycin	Extended-release Tablets	500 mg	Biaxin XL 50775	PIV received prior to 2/5/2009						
Clevidipine	Injectable Emulsion	25 mg/50 mL and 50 mg/100 mL	Cleviprex 22156	7/2/2019	1					10/10/2031
Clindamycin Phosphate	Foam	1%	Evoclin 50801	PIV received prior to 2/5/2009						
Clindamycin Phosphate	Vaginal Cream	2%	Clindesse 50793	2/5/2015						
Clindamycin Phosphate and Tretinoin	Gel	1.2%/0.025%	Ziana 50802	12/17/2010	1	Deferred	6/18/2019	6/12/2015	7/5/2016	8/3/2020
Clindamycin Phosphate and Benzoyl Peroxide	Gel	1% / 5%	Duac 50741	12/11/2008	1	Deferred	6/18/2019	6/26/2012	6/26/2012	11/14/2012

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Clindamycin Phosphate and Benzoyl Peroxide	Gel	1.2%/2.5%	Acanya 50819	12/20/2012	1	Eligible	6/18/2019	6/19/2015	2/19/2019	8/5/2029
Clindamycin Phosphate and Benzoyl Peroxide	Gel	1.2%/3.75%	Onexton 50819	9/30/2015	1	Eligible	6/18/2019	6/5/2018		8/5/2029
Clobetasol Propionate	Emulsion Foam	0.05%	Olux-E 22013	2/25/2010						
Clobetasol Propionate	Topical Foam	0.05%	Olux 21142	6/27/2005						
Clobetasol Propionate	Lotion	0.05%	Clobex 21535	3/27/2006						
Clobetasol Propionate	Spray	0.05%	Clobex 21835	9/29/2008						
Clobetasol Propionate	Topical Shampoo	0.05%	Clobex 21644	1/9/2008						
Clofarabine	Injection	1 mg/mL, 20 mL vial	Clolar 21673	2/23/2012						
Clonidine Hydrochloride	Extended-release Tablets	0.1 mg and 0.2 mg	Jenloga 22331	3/4/2011						
Clonidine Hydrochloride	Extended-release Tablets	0.1 mg and 0.2 mg	Kapvay 22331	3/4/2011						
Clonidine Hydrochloride	Transdermal System	1.1 mg/day 1.2 mg/day 1.3 mg/day	Catapres-TTS 18891							
Clopidogrel Bisulfate	Tablets	75 mg	Plavix 20839							
Clopidogrel Bisulfate	Tablets	300 mg	Plavix 20839	3/4/2009						
Clozapine	Orally Disintegrating Tablets	12.5 mg	Fazaclo 21590	6/5/2008						
Clozapine	Orally Disintegrating Tablets	25 mg and 100 mg	Fazaclo 21590	4/28/2008						
Clozapine	Orally Disintegrating Tablets	150 mg	Fazaclo 21590	4/8/2011						
Clozapine	Orally Disintegrating Tablets	200 mg	Fazaclo 21590	4/18/2011						
Cobicistat	Tablets	150 mg	Tybost 203094	11/14/2016	1					9/3/2029
Colchicine	Capsules	0.6 mg	Mitigare 204820	6/10/2016	1	Eligible	8/27/2019	11/29/2018		8/22/2033
Colchicine	Tablets	0.3 mg	Colcrys 22352	7/19/2019	1					2/17/2029

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Colchicine	Tablets	0.6 mg	Colcrys 22352	12/23/2011						
Colesevelam Hydrochloride *	Powder for Oral Suspension	1.875 g/Package and 3.75 g/Package	Welchol 22362	4/9/2010						
Colesevelam Hydrochloride	Tablets	625 mg	Welchol 21176	7/1/2009						
Colestipol Hydrochloride	Tablets	1 g	Colestid 02222	8/23/2005						
Conjugated Estrogen (Synthetic A)	Tablets	0.3 mg, 0.45 mg and 0.9 mg	Cenestin 20992	3/19/2009						
Conjugated Estrogen (Synthetic A)	Tablets	1.25 mg	Cenestin 20992	11/3/2008						
Conjugated Estrogen (Synthetic A)	Tablets	0.625 mg	Cenestin 20992	3/2/2009						
Conjugated Estrogens	Tablets	0.3 mg and 0.625 mg	Premarin 04782							
Cyanocobalamin	Nasal Spray	500 mcg/spray	Nascobal 21642	4/28/2017	1					8/1/2024
Cyclobenzaprine Hydrochloride	Tablets	10 mg	Flexeril 17821							
Cyclobenzaprine Hydrochloride	Extended-release Capsule	15 mg and 30 mg	Amrix 21777	8/11/2008						
Cyclophosphamide	For Injection	100 mg/vial 200 mg/vial 500 mg/vial 1 g/vial 2 g/vial	Cytosan 12142							
Dabigatran Etexilate Mesylate	Capsules	eq. to 75 mg base and 150 mg base	Pradaxa 22512	10/20/2014						
Dabigatran Etexilate Mesylate	Capsules	eq. to 110 mg base	Pradaxa 22512	12/15/2015						
Dalfampridine	Extended-release Tablets	10 mg	Ampyra 22250	1/22/2014						
Dapagliflozin	Tablets	5 mg and 10 mg	Farxiga 202293	1/8/2018						
Dapagliflozin and Saxagliptan	Tablets	10 mg/5 mg	Qtern 209091	1/8/2018						
Dapagliflozin and Metformin Hydrochloride	Extended-release Tablets	2.5 mg/1000 mg	Xigduo XR 205649	10/29/2018						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Dapagliflozin and Metformin Hydrochloride	Extended-release Tablets	5 mg/500 mg 5 mg/1000 mg 10 mg/500 mg 10 mg/1000 mg	Xigduo XR 205649	1/8/2018						
Dapsone	Gel	7.5%	Aczone 207154	2/13/2017	1	Eligible	7/2/2019	6/26/2019		11/18/2033
Daptomycin	For Injection	500 mg/vial	Cubicin 21572	11/19/2008						
Darifenacin Hydrobromide	Extended-release Tablets	7.5 mg and 15 mg	Enablex 21513	12/22/2008						
Darunavir Ethanolate	Tablets	75 mg, 150 mg and 300 mg	Prezista 21976	6/23/2010	1					12/26/2026
Darunavir Ethanolate	Tablets	400 mg	Prezista 21976	6/23/2010	2					12/26/2026
Darunavir Ethanolate	Tablets	600 mg	Prezista 21976	6/23/2010	3	Deferred	7/2/2019	11/21/2017		12/26/2026
Darunavir Ethanolate	Tablets	800 mg	Prezista 21976	5/14/2013	1					12/26/2026
Dasatinib	Tablets	80 mg and 140 mg	Sprycel 21986	6/17/2011						
Dasatinib	Tablets	20 mg, 50 mg, 70 mg and 100 mg	Sprycel 21986	6/28/2010						
Deferasirox	Tablets for Suspension	125 mg, 250 mg, and 500 mg	Exjade 21882	10/28/2011	1	Eligible	7/2/2019	1/26/2016	3/22/2019	4/5/2019
Deferasirox *	Tablets	90 mg and 360 mg	Jadenu 206910	10/19/2015	1	Extinguished	7/16/2019			4/5/2019
Deferasirox	Tablets	180 mg	Jadenu 206910	4/21/2016	1	Eligible	7/16/2019			11/21/2034
Deferiprone	Tablets	500 mg	Ferriprox 21825	1/29/2016	1	Eligible	8/13/2019	2/8/2019		6/28/2021
Deoxycholic Acid	Injection	10 mg/mL (2 mL)	Kybella 206333	7/13/2018						
Desflurane	Inhalation	99.9%	Suprane 20118	9/11/2008						
Desloratadine	Tablets	5 mg	Clarinex 21165	6/21/2006						
Desloratadine	Orally Disintegrating Tablets	2.5 mg and 5 mg	Clarinex 21165	6/21/2006						
Desloratadine	Oral Solution	0.5 mg/mL	Clarinex Syrup 21300	5/8/2008						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Desloratadine and Pseudoephedrine Sulfate	Extended-release Tablets	2.5 mg/120 mg	Clarinet-D 24 Hour 21313	6/1/2007						
Desloratadine and Pseudoephedrine Sulfate	Extended-release Tablets	5 mg/240 mg	Clarinet-D 24 Hour 21313	6/21/2006						
Desmopressin Acetate	Injection	4 mcg/mL, 1 mL and 10 mL vials	DDAVP 18938							
Desmopressin Acetate	Nasal Spray	0.01%	DDAVP 17922							
Desmopressin Acetate	Tablets	0.1 mg and 0.2 mg	DDAVP 19955							
Desogestrel; Ethinyl Estradiol Tablets	Tablets	0.15mg/ 0.02 mg and 0.01 mg	Mircette 20713							
Desonide	Gel	0.05%	Desonate 21844	12/1/2010						
Desoximetasone	Topical Spray	0.25%	Topicort 204141	12/18/2013						
Desvenlafaxine Succinate	Extended-release Tablets	50 mg and 100 mg	Pristiq 21992	2/29/2012	12	Eligible	6/18/2019	6/29/2015	2/28/2017	2/11/2022
Desvenlafaxine Succinate	Extended-release Tablets	25 mg	Pristiq 21992	5/8/2015						
Dexlansoprazole	Delayed-release Capsules	30 mg	Dexilant 22287	11/30/2010						
Dexlansoprazole	Delayed-release Capsules	60 mg	Dexilant 2287	8/25/2010						
Dexmedetomidine	Injection	100 mcg/mL	Precedex 21038	4/8/2009						
Dexmedetomidine*	Injection	4 mcg/mL, 50 mL and 100 mL vials	Precedex 21038	12/26/2013	1	Extinguished	8/13/2019			1/4/2032
Dexmedetomidine	Injection	4 mcg/mL, 20 mL vials	Precedex 21038	9/30/2015	1	Eligible	7/2/2019	11/29/2018	6/3/2021	1/4/2023
Dexmethylphenidate Hydrochloride	Tablets	2.5 mg	Focalin 21278	7/27/2004						
Dexmethylphenidate Hydrochloride	Tablets	5 mg and 10 mg	Focalin 21278	5/27/2004						
Dexmethylphenidate Hydrochloride	Extended-release Capsules	15 mg	Focalin XR 21802	5/14/2007						
Dexmethylphenidate Hydrochloride	Extended-release Capsules	5 mg, 10 mg and 20 mg	Focalin XR 21802	3/30/2007						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Dexmethylphenidate Hydrochloride	Extended-release Capsules	30 mg	Focalin XR 21802	12/15/2010						
Dexmethylphenidate Hydrochloride	Extended-release Capsules	40 mg	Focalin XR 21802	12/20/2010						
Dexmethylphenidate	Extended-release Capsules	35 mg	Focalin XR 21802	9/29/2011						
Dexmethylphenidate	Extended-release Capsules	25 mg	Focalin XR 21802	9/30/2011						
Dexrazoxane	For Injection	250 mg/vial	Zinecard 20212							
Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate	Extended-release Capsules	5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg	Adderall XR 21303							
Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate	Tablets	5 mg, 10 mg, 20 mg, 30 mg	Adderall 11522	11/18/2009						
Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate	Tablets	7.5 mg, 12.5 mg and 15 mg	Adderall 11522							
Dextromethorphan Polistirex	Extended-release Suspension	30 mg/5 mL	Delsym 18658	1/12/2009						
Dextromethorphan Hydrobromide and Quinidine Sulfate *	Capsules	20 mg/10 mg	Nuedexta 21879	3/7/2011						
Diazepam	Tablets	2 mg, 5 mg and 10 mg	Valium 13263							
Diazepam	Rectal Gel	2.5 mg/0.5 mL 5 mg/mL 10 mg/2 mL 15 mg/3 mL 20 mg/4 mL	Diastat 20648	3/23/2004						
Diazepam	Rectal Gel	5 mg/mL, 4mL pre-filled syringe	Diastat Acudial 20648	12/8/2008						
Diazepam	Rectal Gel	5 mg/mL, 2mL pre-filled syringe	Diastat Acudial 20648	12/23/2008						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Diclofenac Potassium	Oral Solution (Sachet)	50 mg	Cambia 22165	1/24/2011						
Diclofenac Potassium	Capsules	25 mg	Zipsor 22202	11/14/2012						
Diclofenac Sodium	Injection	37.5 mg/mL, 1 mL single-dose vials	Dyloject 22396	12/15/2015	1	Eligible	7/2/2019	6/18/2019		3/22/2027
Diclofenac Sodium	Topical Gel	3%	Solaraze 21005	12/16/2009						
Diclofenac Sodium	Topical Solution	1.5%	Pennsaid 20947	7/11/2012						
Diclofenac Sodium	Topical Solution	2.0%	Pennsaid 204623	6/3/2014						
Diclofenac	Capsules	18 mg and 35 mg	Zorvolex 204592	6/6/2014						
Diclofenac Epolamine	Topical Patch	1.3%	Flector 21234	6/26/2015	1	Extinguished	7/2/2019			4/13/2019
Diclofenac Sodium and Misoprostol*	Delayed-release Tablets	50 mg/0.2 mg	Arthrotec 20607	6/29/2009						
Diclofenac Sodium and Misoprostol*	Delayed-release Tablets	75 mg/0.2 mg	Arthrotec 20607	11/28/2008						
Didanosine	Delayed-release Capsules	200 mg, 250 mg and 400 mg	Videx EC 21183	6/1/2004						
Difluprednate	Ophthalmic Emulsion	0.05%	Durezol 22212	5/1/2014	1	Extinguished	7/2/2019			5/18/2019
Diltiazem Hydrochloride	Extended-release Capsules	60 mg, 90 mg and 120 mg	Cardizem SR 19471							
Diltiazem Hydrochloride	Extended-release Capsules	120 mg, 180 mg and 240 mg	Dilacor XR 20092							
Diltiazem Hydrochloride	Extended-release Capsules	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	Cardizem CD 20062							
Diltiazem Hydrochloride	Extended-release Capsules	120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg	Tiazac 20401							
Diltiazem Hydrochloride	Extended-release Tablets	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	Cardizem LA 21392	8/30/2005						
Diltiazem Hydrochloride	Extended-release Tablets	420 mg	Cardizem LA 21392	4/25/2005						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Dimethyl Fumarate	Delayed-release Capsules	120 mg and 240 mg	Tecfidera 204063	3/27/2017	29					2/7/2028
Divalproex Sodium	Delayed-release Tablets	125 mg, 250 mg and 500 mg	Depakote 18723							
Divalproex Sodium*	Extended-release Tablets	250 mg	Depakote ER 21168	5/3/2004						
Divalproex Sodium	Extended-release Tablets	500 mg	Depakote ER 21168	2/8/2005						
Docetaxel	Injection	40 mg/mL, 0.5 mL and 2 mL vials	Taxotere 20449	6/30/2009						
Dofetilide	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	Tikosyn 20931	5/1/2014	1	Eligible	8/13/2019	6/6/2016	6/7/2016	10/9/2018
Dolutegravir Sodium	Tablets	10 mg, 25 mg and 50 mg	Tivicay 204790	8/14/2017						
Dolutegravir Sodium and Lamivudine New	Tablets	50 mg/300 mg	Dovato 211994	7/30/2019	1					12/8/2029
Donepezil Hydrochloride	Tablets	5 mg and 10 mg	Aricept 20690							
Donepezil Hydrochloride	Orally Disintegrating Tablets	5 mg and 10 mg	Aricept ODT 21720	6/30/2010						
Donepezil Hydrochloride	Tablets	23 mg	Aricept 22568	7/9/2013						
Doripenem	Injection	250 mg/vial and 500 mg/vial	Doribax 22106	10/12/2011						
Dorzolamide Hydrochloride	Ophthalmic Solution	2%	Trusopt 20408	10/11/2005						
Dorzolamide Hydrochloride and Timolol Maleate	Ophthalmic Solution	2%/0.5%	Cosopt 20869	10/11/2005						
Doxazosin Mesylate	Tablets	1 mg, 2 mg, 4 mg and 8 mg	Cardura 19668							
Doxepin Hydrochloride	Tablets	3 mg and 6 mg	Silenor 22036	9/16/2010	2	Eligible	6/18/2019	7/26/2013		2/17/2020
Doxercalciferol	Capsules	1 mcg	Hectorol 20862	2/12/2010						
Doxercalciferol	Capsules	0.5 mcg and 2.5 mcg	Hectorol 20862	3/25/2009						
Doxercalciferol*	Injection	2 mcg/mL, 2 mL ampules	Hectorol 21027	10/15/2007						
Doxercalciferol*	Injection	2 mcg/mL, 1 mL in 2 mL vial	Hectorol 21027	12/28/2011						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Doxycycline	Delayed-release Capsules	40 mg	Oracea 50805	12/11/2008						
Doxycycline Hyclate	Delayed-release Tablets	75 mg and 100 mg	Doryx 50795	PIV received prior to 2/5/2009						
Doxycycline Hyclate	Delayed-release Tablets	150 mg	Doryx 50795	12/19/2008						
Doxycycline Hyclate	Delayed-release Tablets	200 mg	Doryx 50795	5/19/2014						
Doxycycline Hyclate	Delayed-release Tablets	80 mg	Doryx 50795	7/1/2015						
Doxycycline Hyclate	Delayed-release Tablets	50 mg	Doryx 50795	11/5/2015						
Doxycycline Hyclate	Delayed-release Tablets	60 mg and 120 mg	Doryx MPC 50795	9/28/2017						
Doxylamine Succinate and Pyridoxine Hydrochloride	Delayed-release Tablets	10 mg/10 mg	Diclegis 21876	8/1/2013	1	Extinguished	7/2/2019	8/19/2016	6/21/2019	6/21/2021
Doxylamine Succinate and Pyridoxine Hydrochloride	Extended-release Tablets	20 mg/20 mg	Bonjesta 209661	8/28/2018						
Dronabinol	Oral Solution	5 mg/mL	Syndros	4/17/2017						
Dronedarone Hydrochloride	Tablets	400 mg	Multaq 22425	7/1/2013						
Drospirenone and Estradiol	Tablets	0.5 mg/1 mg	Angeliq 21355	12/26/2007						
Drospirenone and Estradiol	Tablets	0.25 mg/0.5 mg	Angeliq 21355	1/8/2015						
Drospirenone and Ethinyl Estradiol	Tablets	3 mg/0.02 mg	Yaz 21676	9/29/2006						
Drospirenone and Ethinyl Estradiol	Tablets	3 mg/0.03 mg	Yasmin 21098	1/7/2005						
Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium	Tablets	3 mg/0.03 mg/0.451 mg and 0.451 mg	Safyral 22574	9/28/2012						
Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium	Tablets	3 mg/0.02 mg/0.451 mg and 0.451 mg	Beyaz 22532	11/13/2012						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Duloxetine Hydrochloride	Delayed-release Capsules	20 mg, 30 mg and 60 mg	Cymbalta 21427	8/4/2008						
Duloxetine Hydrochloride	Delayed-release Capsules	40 mg	Cymbalta 21427	5/10/2012						
Dutasteride	Capsules	0.5 mg	Avodart 21319	10/29/2007						
Dutasteride and Tamsulosin Hydrochloride	Capsules	0.5 mg/0.4 mg	Jalyn 22460	10/26/2010						
Edoxaban Tosylate	Tablets	15 mg, 30 mg and 60 mg	Savaysa 206316	1/28/2019						
Efavirenz	Tablets	600 mg	Sustiva 21360	4/9/2009						
Efavirenz	Capsules	50 mg, 100 mg and 200 mg	Sustiva 20972	11/3/2016	1	Eligible	7/2/2019	12/15/2017	12/21/2017	4/6/2019
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	Tablets	600 mg/200 mg/300 mg	Atripla 21937	12/29/2008						
Efinaconazole	Topical Solution	10%	Jublia 203567	6/6/2018	19					10/2/2034
Eletriptan Hydrobromide *	Tablets	20 mg and 40 mg	Relpax 21016	3/29/2010						
Eliglustat Tartrate	Capsules	84 mg	Cerdelga 205494	8/20/2018						
Eltrombopag Olamine	Tablets	50 mg and 75 mg	Promacta 22291	1/7/2014	1					2/1/2028
Eltrombopag Olamine	Tablets	12.5 mg and 25 mg	Promacta 22291	2/4/2014	1					2/1/2028
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate	Tablets	150 mg, 150 mg, 200 mg, 300 mg	Stribild 203100	10/4/2018						
Eluxadoline	Tablets	75 mg and 100 mg	Viberzi 206940	5/28/2019	6					3/14/2033
Empagliflozin	Tablets	10 mg and 25 mg	Jardiance 204629	8/1/2018						
Empagliflozin and Metformin Hydrochloride	Tablets	5 mg/500 mg 5 mg/1000 mg 12.5 mg/500 mg 12.5 mg/1000 mg	Synjardy 206111	8/1/2018						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Empagliflozin and Metformin Hydrochloride	Extended-release Tablets	5 mg/1000 mg 10 mg/1000 mg 12.5 mg/1000 mg 25 mg/1000 mg	Synjardy XR 208658	8/1/2018						
Empagliflozin and Linagliptin	Tablets	10 mg/5 mg and 25 mg/5 mg	Glyxambi 206073	8/1/2018						
Emtricitabine	Capsules	200 mg	Emtriva 21500	7/16/2012						
Emtricitabine and Tenofovir Disoproxil Fumarate	Tablets	200 mg/300 mg	Truvada 21752	9/26/2008	1	Extinguished	8/13/2019	6/8/2017		3/9/2021
Emtricitabine and Tenofovir Disoproxil Fumarate	Tablets	100 mg/150 mg 133 mg/200 mg 167 mg/250 mg	Truvada 21752	5/19/2017	1	Eligible	8/13/2019	8/22/2018		3/9/2021
Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate	Tablets	200 mg/25 mg/300 mg	Complera 202123	5/20/2015						
Enalapril Maleate	Tablets	2.5 mg, 5 mg, 10 mg and 20 mg	Vasotec 18998							
Enalapril Maleate	Powder for Oral Solution	1 mg/mL	Epaned Kit 204308	6/21/2016						
Enalapril Maleate	Oral Solution	1 mg/mL	Epaned 208686	8/31/2018						
Enoxaparin Sodium	Injection	100 mg/mL, 0.3 mL, 0.4 mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes	Lovenox 20164							
Enoxaparin Sodium	Injection	150 mg/mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes	Lovenox 20164							
Enoxaparin Sodium	Injection	100 mg/mL, 3 mL vials	Lovenox 20164	12/7/2006						
Entacapone	Tablets	200 mg	Comtan 20796	4/11/2007						
Entecavir	Tablets	0.5 mg and 1 mg	Baraclude 21797	6/14/2010						
Enzalutamide	Capsules	40 mg	Xtandi 203415	8/31/2016	3					8/13/2027
Epinastine Hydrochloride	Ophthalmic Solution	0.05%	Elestat 21565	10/14/2008						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Epinephrine	Injection (Auto-injector)	0.15 mg/0.3 mL and 0.3 mg/0.3 mL	Epipen and Epipen Jr. 19430	7/20/2009	1	Deferred	8/27/2019	8/16/2018	8/19/2019	9/11/2025
Epinephrine	Injection	1 mg/mL ampules	Adrenalin 204200	3/9/2016						
Epinephrine New	Injection	30 mg/30 mL	Adrenalin 204640	8/20/2018	1					3/13/2035
Eplerenone	Tablets	25 mg and 50 mg	Inspra 21437	9/27/2006						
Epoprostenol Sodium	Injection	0.5 mg/vial and 1.5 mg/vial	Veletri 22260	3/31/2017	1					3/15/2027
Eptifibatide	Injection	0.75 mg/mL, 100 mL vial	Integrilin 21437	6/5/2009						
Eptifibatide	Injection	2 mg/mL, 10 mL vial	Integrilin 20718	9/30/2008						
Eptifibatide	Injection	2 mg/mL, 100 mL vial	Integrilin 20718	12/18/2008						
Eprosartan Mesylate	Tablets	400 mg and 600 mg	Teveten 20738	5/10/2010						
Erlotinib Hydrochloride	Tablets	25 mg, 100 mg and 150 mg	Tarceva 21743	11/18/2008	2	Eligible	6/18/2019	6/11/2014	5/9/2019	11/9/2020
Ertapenem*	Injection	1 g/vial	Invanz 21337	12/21/2012						
Escitalopram Oxalate	Capsules	5 mg	Lexapro 21323	8/17/2005						
Escitalopram Oxalate	Capsules	10 mg and 20 mg	Lexapro 21323	3/30/2005						
Escitalopram Oxalate	Tablets	5 mg, 10 mg and 20 mg	Lexapro 21323							
Eslicarbazepine Acetate	Tablets	200 mg, 400 mg, 600 mg and 800 mg	Aptiom 22416	11/8/2017	7					8/24/2032
Esmolol Hydrochloride	Injection	10 mg/mL, 10 mL vial	Brevibloc 19386							
Esmolol Hydrochloride	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags	Brevibloc 19386	1/31/2014						
Esomeprazole Magnesium	Delayed-release Capsules	20 mg and 40 mg	Nexium 21153	8/5/2005						
Esomeprazole Magnesium	Delayed-release Capsules	20 mg	Nexium (OTC) 204655	4/24/2014						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Esomeprazole Magnesium	Delayed-release for Oral Suspension	20 mg and 40 mg	Nexium 21957	8/1/2013						
Esomeprazole Magnesium	Delayed-release for Oral Suspension	10 mg	Nexium 22101	7/6/2018	1					11/3/2019
Esomeprazole Magnesium	Delayed-release for Oral Suspension	2.5 mg and 5 mg	Nexium 21957	9/24/2018	1					11/3/2019
Esomeprazole	Delayed-release Tablets	20 mg	Nexium 24HR (OTC) 207920	9/9/2016	1	Eligible	7/2/2019	3/5/2019		11/3/2019
Esomeprazole Sodium	For Injection	20 mg/vial and 40 mg/vial	Nexium IV 21689	11/23/2009						
Estradiol	Transdermal System	0.025 mg/day 0.0375 mg/day 0.05 mg/days 0.075 mg/day 0.1 mg/day	Vivelle Dot 20538	4/27/2010						
Estradiol	Transdermal System	0.0375 mg/day and 0.06 mg/day	Climara 20375							
Estradiol	Transdermal System	0.05 mg/day and 0.1 mg/day	Climara 20375	9/12/2005						
Estradiol	Vaginal Tablets	10 mcg	Vagifem 20908	1/2/2013						
Estradiol	Transdermal System	0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	Minivelle 203752	8/18/2014						
Estradiol	Transdermal System	0.025 mg/day	Minivelle 203752	5/8/2015						
Estradiol; Estradiol and Norgestimate	Tablets	1 mg; 1 mg and 0.09 mg	Prefest 21040							
Estradiol Valerate and Dienogest	Tablets	3 mg;2 mg/2 mg;2 mg/3 mg and 1 mg	Natazia 22252	10/22/2010						
Eszopiclone	Tablets	1 mg, 2 mg and 3 mg	Lunesta 21476	12/15/2008						
Ethinyl Estradiol and Etonogestrel *	Vaginal Ring	0.015 mg/24 hour 0.12 mg/24 hour	Nuvaring 21187	6/17/2013						
Etodolac	Extended-release Tablets	400 mg, 500 mg and 600 mg	Lodine XL 20584							
Everolimus	Tablets	0.25 mg, 0.5 mg, and 0.75 mg	Zortress 21560	9/30/2013						
Everolimus	Tablets	10 mg	Afinitor 22334	6/18/2014	1					12/6/2019

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Everolimus	Tablets	2.5 mg, 5 mg, and 7.5 mg	Afinitor 22334	12/10/2014	1					12/6/2019
Everolimus	Tablets for Oral Suspension	2 mg, 3 mg and 5 mg	Afinitor Disperz 203985	12/30/2016						
Exenatide	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe	Byetta 21773	6/11/2014						
Ezetimibe	Tablets	10 mg	Zetia 21445	10/25/2006	1	Eligible	6/18/2019	6/26/2015	12/12/2016	1/25/2022
Ezetimibe and Simvastatin *	Tablets	10 mg/10 mg 10 mg/20 mg 10 mg/40 mg 10 mg/80 mg	Vytorin 21687	7/27/2009						
Famciclovir	Tablets	125 mg, 250 mg and 500 mg	Famvir 20363	12/28/2004						
Famotidine	Injection	10 mg/mL, 2 mL vials; unpreserved	Pepcid							
Famotidine	Injection	10 mg/mL, 4 mL and 20 mL vials; preserved	Pepcid							
Famotidine	Injection	10 mg/mL, 50 mL vial, pharmacy bulk package; unpreserved	Pepcid							
Famotidine	Tablets	10 mg (OTC)	Pepcid AC							
Famotidine	Tablets	20 mg and 40 mg	Pepcid 19462							
Famotidine	Tablets (Chewable)	10 mg (OTC)	Pepcid AC (chewable) 20801							
Febuxostat	Tablets	40 mg and 80 mg	Uloric 21856	2/13/2013	10	Eligible	8/27/2019	7/1/2019		3/8/2024
Felodipine	Extended-release Tablets	2.5 mg, 5 mg and 10 mg	Plendil ER 19834							
Fenofibrate*	Tablets	40 mg and 120 mg	Fenoglide 22118	3/17/2010						
Fenofibrate	Capsules	43 mg and 130 mg	Antara 21695	9/15/2008						
Fenofibrate Choline	Delayed-release Capsules	45 mg	Trilipix 22224	9/2/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Fenofibrate Choline	Delayed-release Capsules	135 mg	Trilipix 22224	9/1/2009						
Fenofibrate	Capsules	67 mg, 134 mg and 200 mg	Tricor 19304							
Fenofibrate	Tablets	48 mg	Tricor 21656	7/1/2008						
Fenofibrate	Tablets	54 mg, 107 mg and 160 mg	Tricor 21203							
Fenofibrate	Tablets	145 mg	Tricor 21656	10/19/2007						
Fentanyl	Transdermal Extended-release Film	0.6 mg/24 hr 1.2 mg/ 24 hr 1.8 mg/ 24 hr 2.4 mg/ 24 hr	Duragesic 19813							
Fentanyl Citrate*	Buccal Tablets	0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg	Fentora 21947	11/13/2007						
Fentanyl Citrate	Lozenges	0.2 mg	Actiq 20747	10/29/2004						
Fentanyl Citrate	Lozenges	0.4 mg	Actiq 20747	10/6/2004						
Fentanyl Citrate	Lozenges	0.6 mg	Actiq 20747	12/20/2004						
Fentanyl Citrate	Lozenges	0.8 mg, 1.2 mg and 1.6 mg	Actiq 20747	11/22/2004						
Fentanyl	Sublingual Spray	0.4 mg/spray	Subsys 202788	5/22/2017						
Fentanyl	Sublingual Spray	1.1 mg/spray, 1.2 mg/spray, 0.6 mg/spray, 0.8 mg/spray, 1.2 mg/spray, 1.6 mg/spray	Subsys 202788	12/7/2017						
Fentanyl Citrate	Sublingual Tablets	0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg	Abstral 22510	6/19/2014						
Ferric Carboxymaltose	Injection	750 mg/15 mL	Injectafer 203565	3/27/2019	1					2/13/2027
Ferumoxytol	Injection	30 mg/mL, 17 mL single-use vials	Feraheme 22180	12/4/2015	1					6/30/2023

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Fesoterodine Fumarate	Extended-release Tablets	4 mg and 8 mg	Toviaz 22030	10/31/2012						6/7/2027
Fexofenadine Hydrochloride	Oral Suspension	30 mg/5 mL	Allegra	1/25/2010						
Fexofenadine Hydrochloride	Capsules	60 mg	Allegra 20625							
Fexofenadine Hydrochloride	Tablets	30 mg, 60 mg and 180 mg	Allegra 20872							
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride	Extended-release Tablets	60 mg/120 mg	Allegra-D 20786							
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride	Extended-release Tablets	180 mg/240 mg	Allegra-D 24 Hour 21704	6/6/2007						
Fidaxomicin	Tablets	200 mg	Dificid 201699	5/27/2015						
Finasteride	Tablets	1 mg	Propecia 20788							
Finasteride	Tablets	5 mg	Proscar 20180							
Fingolimod	Capsules	0.5 mg	Gilenya 22527	9/22/2014						
Fingolimod	Capsules	0.25 mg	Gilenya 22527	7/18/2018	1					3/30/2032
Flecainide Acetate	Tablets	50 mg, 100 mg and 150 mg	Tambocor 18830							
Fluconazole	For Oral Suspension	50 mg/5 mL and 200 mg/5 mL	Diflucan for Oral Suspension 20090							
Fluconazole	Tablets	50 mg, 100 mg, 150 mg and 200 mg	Diflucan 19949							
Flunisolide	Nasal Solution	0.025%	Nasalide 18148							
Fluocinonide	Cream	0.1%	Vanos 21758	1/31/2008						
Fluocinonide	Ointment	0.05%	Lidex 16909							
Fluorouracil	Cream	0.5%	Carac 20985	7/29/2011						
Fluoxetine Hydrochloride	Tablets	10 mg and 20 mg	Prozac 20974							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Fluoxetine Hydrochloride	Capsules	10 mg, 20 mg and 40 mg	Prozac 18936							
Fluoxetine Hydrochloride	Delayed-release Capsules	90 mg	Prozac Weekly 21235							
Fluoxetine Hydrochloride	Oral Solution	20 mg (base)/5 mL	Prozac 20101							
Fluoxetine Hydrochloride	Capsules	10 mg and 20 mg	Sarafem 18936							
Flutamide	Capsules	125 mg	Eulexin 18554							
Fluticasone Furoate	Nasal Spray	27.5 mcg	Veramyst	7/15/2011						
Fluticasone Propionate	Lotion	0.05%	Cutivate 21152	7/28/2008						
Fluticasone Propionate	Inhalation Aerosol	0.11 mcg/inh	Flovent HFA 21433	12/23/2016	1					8/26/2026
Fluvastatin	Capsules	20 mg and 40 mg	Lescol 20261	6/4/2008						
Fluvastatin Sodium	Extended-release Tablets	80 mg	Lescol XL 21192	3/15/2007						
Fluvoxamine Maleate	Extended-release Capsules	100 mg	Luvox CR 22033	4/20/2009						
Fluvoxamine Maleate	Extended-release Capsules	150 mg	Luvox CR 22033	4/13/2009						
Formoterol Fumarate*	Inhalation Solution	0.02 mg/2 mL	Perforomist 22007	1/21/2009						
Fosamprenavir Calcium	Tablets	700 mg	Lexiva 21548	1/18/2012						
Fosaprepitant Dimeglumine*	Injection	115 mg/vial	Emend 22023	1/25/2012						
Fosaprepitant Dimeglumine*	Injection	150 mg/vial	Emend 22023	1/25/2012						
Fosinopril Sodium	Tablets	10 mg, 20 mg and 40 mg	Monopril 19915							
Fosinopril Sodium and Hydrochlorothiazide	Tablets	10 mg/12.5 mg and 20 mg/12.5 mg	Monopril HCT 20286							
Frovatriptan Succinate	Tablets	2.5 mg	Frova 21006	3/9/2011						
Fulvestrant*	Injection	50 mg/mL, 2.5 mL and 5 mL syringe	Faslodex 21344	10/1/2009	1	Extinguished	7/16/2019			1/9/2021
Gabapentin	Capsules	100 mg, 300 mg and 400 mg	Neurontin 20235							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Gabapentin	Tablets	100 mg, 300 mg and 400 mg	Neurontin 20235							
Gabapentin	Oral Solution	250 mg/5 mL	Neurontin 21129							
Gabapentin	Tablets	600 mg and 800 mg	Neurontin 20882							
Gabapentin	Tablets	300 mg and 600 mg	Gralise 22544	10/31/2011						
Gabapentin Enacarbil	Extended-release Tablets	300 mg and 600 mg	Horizant 22399	4/29/2019	1					6/10/2029
Galantamine Hydrobromide	Extended-release Capsules	8 mg	Razadyne ER 21615	3/2/2006						
Galantamine Hydrobromide	Extended-release Capsules	16 mg and 24 mg	Razadyne ER 21615	3/11/2006						
Galantamine Hydrobromide	Tablets	4 mg, 8 mg and 12 mg	Razadyne 21169	2/28/2005						
Ganciclovir Sodium	Capsules	250 mg and 500 mg	Cytovene 20460							
Ganirelix Acetate	Injection	250 mcg/0.5 mL, 1 mL PFS	Ganirelix Acetate 21057	3/30/2012						
Gatifloxacin	Injection	10 mg/mL, 20 mL and 40 mL vials	Tequin	11/24/2004						
Gatifloxacin	Ophthalmic Solution	0.3 %	Zymar 21493	7/19/2007						
Gatifloxacin	Ophthalmic Solution	0.5 %	Zymaxid 22548	12/7/2010						
Gatifloxacin	Tablets	200 mg and 400 mg	Tequin							
Gatifloxacin in Dextrose 5% in Plastic Container	Injection	2 mg/mL, 100 mL and 200 mL containers (plastic)	Tequin	12/13/2004						
Gemcitabine	For Injection	200 mg/vial	Gemzar 20509	11/1/2005						
Gemcitabine	For Injection	1g/vial	Gemzar 20509	11/14/2005						
Gemcitabine	For Injection	2 g/vial	Gemzar	8/24/2007						
Gemifloxacin Mesylate	Tablets	320 mg	Factive 21158	3/4/2008	1	Eligible	6/18/2019	6/15/2015		9/21/2019
Glatiramer Acetate	Injection	20 mg/mL, 1mL pre-filled syringe	Copaxone 20622	12/27/2007						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Glatiramer Acetate	Injection	40 mg/mL, 1 mL pre-filled syringe	Copaxone 20622	2/26/2014						
Glimepiride and Rosiglitazone Maleate	Tablets	1 mg/4 mg 2 mg/4 mg 4 mg/4 mg	Avandaryl 21700	12/22/2006						
Glimepiride and Rosiglitazone Maleate	Tablets	8 mg/2 mg 8 mg/4 mg	Avandaryl 21700	5/30/2008						
Glipizide	Extended-release Tablets	2.5 mg, 5 mg and 10 mg	Glucotrol XL 20329							
Glyburide	Tablets	1.5 mg, 3 mg, 4.5 mg and 6 mg	Glynase 20051							
Glyburide/ Metformin Hydrochloride	Tablets	1.25mg/250 mg 2.5 mg/500 mg 5 mg/500 mg	Glucovance 21178							
Glycerol Phenylbutyrate	Oral Liquid	1.1 g/mL	Ravicti 203284	11/19/2013	1	Eligible	8/13/2019			3/9/2032
Glycopyrrolate *	Tablets	1 mg	Robinul 12827	8/14/2009						
Glycopyrrolate	Tablets	1.5 mg	Robinul Forte	5/6/2009						
Glycopyrrolate	Tablets	2 mg	Robinul Forte 12827	10/12/2010						
Glycopyrrolate	Oral Solution	1 mg/5 mL	Cuvposa 22571	6/20/2012						
Granisetron Hydrochloride	Injection	0.1 mg/mL, 1 mL single dose vial	Kytril 20239	3/8/2007						
Granisetron Hydrochloride	Injection	1 mg/mL, 1 mL vials	Kytril 20239	6/1/2004						
Granisetron Hydrochloride	Injection	1 mg/mL, 4 mL multi-dose vials	Kytril 20239	7/19/2004						
Granisetron Hydrochloride	Transdermal System	3.1 mg/24 hrs	Sancuso 22198	10/9/2015						
Guaifenesin *	Extended-release Tablets	600 mg and 1.2 gm	Mucinex 21282	6/9/2006						
Guaifenesin and Dextromethorphan	Extended-release Tablets	600 mg/30 mg and 1200 mg/60 mg	Mucinex DM 21620	12/17/2008						
Guaifenesin and Pseudoephedrine Hydrochloride	Extended-release Tablets	600 mg/60 mg and 1200 mg/120 mg	Mucinex-D 21585	12/29/2008						
Guanfacine Hydrochloride	Extended-release Tablets	1 mg, 2 mg, 3 mg and 4 mg	Intuniv 22037	12/29/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Halobetasol Propionate	Lotion	0.05%	Ultavate 208183	1/24/2018						
Halobetasol Propionate	Lotion	0.01%	Bryhali 209355	5/15/2019	1					11/2/2031
Hydrocodone Bitartrate	Extended-release Capsules	10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg	Zohydro ER 202880	2/26/2014	1					11/1/2019
Hydrocodone Bitartrate and Ibuprofen	Tablets	2.5 mg/200 mg	Vicoprofen	2/24/2006						
Hydrocodone Bitartrate and Ibuprofen	Tablets	5 mg/200 mg	Vicoprofen	5/27/2005						
Hydrocodone Bitartrate and Ibuprofen	Tablets	7.5 mg/200 mg	Vicoprofen 20716							
Hydrocodone Bitartrate and Ibuprofen	Tablets	10 mg/200 mg	Vicoprofen							
Hydrocodone Bitartrate	Extended-release Tablets	20 mg, 60 mg, and 120 mg	Hysingla ER 206627	4/15/2015	1					12/21/2031
Hydrocodone Bitartrate	Extended-release Tablets	30 mg, 40 mg, 80 mg, and 100 mg	Hysingla ER 206627	5/8/2015	1					12/21/2031
Hydrocortisone Butyrate	Cream	0.10%	Locoid Lipocream 20769	6/28/2010						
Hydrocortisone Butyrate	Lotion	0.10%	Locoid 22076	8/31/2016						
Hydromorphone Hydrochloride	Extended-release Tablets	8 mg and 12 mg	Exlago 21217	9/2/2010						
Hydromorphone Hydrochloride	Extended-release Tablets	16 mg	Exlago 21217	8/2/2010						
Hydromorphone Hydrochloride	Oral Solution	5 mg/5mL	Dilaudid 19891	2/25/2011						
Hydromorphone Hydrochloride	Injection	10 mg/mL	Dilaudid-HP 19034	11/4/2011						
Hydromorphone Hydrochloride	Injection	2 mg/mL	Dilaudid 19034	6/22/2011						
Hydromorphone Hydrochloride	Tablets	2 mg, 4 mg, and 8 mg	Dilaudid 19892	8/5/2013						
Ibandronate Sodium*	Injection	1 mg/mL, 3 mL Vial	Boniva 21858	8/31/2007						
Ibandronate Sodium	Tablets	2.5 mg and 150 mg	Boniva 21455	5/16/2007						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Ibuprofen	Capsules	70 mg	Imbruvica 205552	12/14/2018						
Ibuprofen	Capsules	140 mg	Imbruvica 205552	11/13/2017						
Ibuprofen	Tablets	140 mg and 560 mg	Imbruvica 210563	11/5/2018						
Ibuprofen	Tablets	280 mg and 420 mg	Imbruvica 210563	12/14/2018						
Ibuprofen	Oral Drops	40 mg/mL	Children's Motrin Drops 20603							
Ibuprofen	Oral Suspension	50 mg/1.25 mL	Concentrated Motrin Infant Drops	6/29/2007						
Ibuprofen	Oral Suspension	100 mg/5 mL (Rx)	Motrin							
Ibuprofen	Oral Suspension	100 mg/5 mL (OTC)	Children's Motrin							
Ibuprofen	Chewable Tablets	50 mg and 100 mg	Children's Motrin, Junior Strength Motrin 20601							
Ibuprofen Lysine	Injection	10 mg/mL, 2 mL vials	Neoprofen 21903	10/1/2010						
Ibuprofen and Diphenhydramine Hydrochloride	Capsules	200 mg/25 mg	Advil PM 21393	2/16/2016						
Ibuprofen and Diphenhydramine Citrate	Tablets	200 mg/38 mg	Advil PM 21394	12/28/2017						
Ibuprofen and Famotidine	Tablets	800 mg/26.6 mg	Duexis 22519	12/6/2011						
Ibuprofen and Pseudoephedrine Hydrochloride	Oral Suspension	100 mg/ 15 mg per 5 mL	Children's Motrin Cold							
Ibuprofen and Pseudoephedrine Hydrochloride	Tablets	200 mg/30 mg	Advil Cold and Sinus							
Ibuprofen Potassium and Pseudoephedrine Hydrochloride	Capsules	200 mg/30 mg	Advil Cold and Sinus	12/27/2004						
Icatibant	Injection	10 mg/mL	Firazyr 22150	8/25/2015	2	Extinguished	8/13/2019			7/15/2019

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Icosapent Ethyl	Capsules	1 g	Vascepa 202057	7/26/2016	4					4/29/2030
Icosapent Ethyl	Capsules	500 mg	Vascepa 202057	8/29/2017	1					4/29/2030
Ifosfamide	For Injection	1 g/vial and 3 g/vial	Ifex 19763							
Ifosfamide	Injection	50 mg/mL, 20 mL vials and 60 mL vials	Ifex							
Ifosfamide/ Mesna	For Injection/ Injection Kit	1 g/vial; 100 mg/mL, 10 mL vials and 3 g/vial; 100 mg/mL, 10 mL vials	Ifex/ Mesnex Kit 19763							
Ifosfamide/ Mesna	Injection/ Injection Kit	50 mg/mL, 20 mL and 60 mL vials; 100 mg/mL, 10 mL vial	Ifex/ Mesnex Kit							
lloperidone	Tablets	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg	Fanapt 22192	5/6/2013	1	Extinguished	6/18/2019			11/15/2016
Imatinib Mesylate	Tablets	100 mg and 400 mg	Gleevec 21588	3/12/2007	1	Non-forfeiture	6/18/2019	12/3/2015	2/1/2016	11/23/2019
Imatinib Mesylate*	Capsules	400 mg	Gleevec	1/24/2014						
Imiquimod	Cream	5%	Aldara 20723	10/17/2006						
Imiquimod	Cream	2.5%	Zyclara 22483	6/17/2014						
Imiquimod	Cream	3.75%	Zyclara 22483	8/8/2012	1	Non-Forfeiture	7/16/2019			12/11/2029
Indomethacin	Extended-release Capsules	75 mg	Indocin SR 18185							
Ingenol Mebutate	Gel	0.05%	Picato 202833	1/27/2016	2	Eligible	8/13/2019	1/9/2019		7/6/2027
Ingenol Mebutate	Gel	0.015%	Picato 202833	1/27/2016	2	Eligible	8/13/2019	1/7/2019		7/6/2027
Irbesartan	Tablets	75 mg, 150 mg and 300 mg	Avapro 20757	5/25/2004						
Irbesartan and Hydrochlorothiazide	Tablets	150 mg/12.5 mg and 300 mg/12.5 mg	Avalide 20758	11/10/2004						
Irbesartan and Hydrochlorothiazide	Tablets	300 mg/25 mg	Avalide 20758	6/6/2006						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Irinotecan Hydrochloride	Injection	20 mg/mL, 2 mL and 5 mL vials	Camptosar 20571	7/26/2004						
Isotretinoin	Capsules	30 mg and 40 mg	Absorica 21951	12/31/2012						
Isotretinoin	Capsules	20 mg	Absorica 21951	1/7/2013						
Isotretinoin	Capsules	10 mg	Absorica 21951	6/19/2013						
Isotretinoin	Capsules	35 mg	Absorica 21951	11/25/2015						
Isotretinoin	Capsules	25 mg	Absorica 21951	5/16/2016						
Itraconazole	Capsules	100 mg	Sporanox 20083							
Itraconazole	Oral Solution	10 mg/mL	Sporanox 20657	5/3/2013						
Ivermectin	Lotion	0.50%	Sklice 202736	9/1/2017						
Ivermectin	Cream	1%	Soolantra 206255	12/30/2016	1					3/13/2034
Ixabepilon	Injection	15 mg/vial and 45 mg/vial, single-use vials	Ixempra Kit 22065	4/16/2012						
Ketoconazole	Foam	2%	Extina 21738	7/30/2009						
Ketoprofen	Capsules	25 mg, 50 mg and 75 mg	Orudis 18754							
Ketorolac Tromethamine	Injection	15 mg/mL and 30 mg/mL	Toradol 19698							
Ketorolac Tromethamine	Ophthalmic Solution	0.45%	Acuvail 22427	8/24/2011						
Ketorolac Tromethamine	Ophthalmic Solution	0.4%	Acular LS 21528	1/28/2005						
Ketorolac Tromethamine	Tablets	10 mg	Toradol 19645							
Ketorolac Tromethamine*	Nasal Spray	15.75 mg/spray	Sprix 22382	3/12/2012						
Ketotifen Fumarate	Ophthalmic Solution	0.025%	Zaditor 21066	12/23/2004						
Lacosamide	Oral Solution	10 mg/mL	Vimpat 22255	10/29/2012						
Lacosamide	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	Vimpat 22253	10/29/2012						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Lacosamide*	Injection	10 mg/mL, 20 mL	Vimpat 22254	6/30/2016						
Lactulose	Oral Syrup	10 g/15 mL	Cephulac 17657							
Lactulose	Oral Syrup	10 g/15 mL	Chronulac 17884							
Lamivudine*	Tablets	100 mg	Epivir-HBV	10/31/2007						
Lamivudine	Tablets	150 mg and 300 mg	Epivir	10/16/2007						
Lamivudine and Zidovudine	Tablets	150 mg/300 mg	Combivir	6/26/2007						
Lamivudine	Oral Solution	10 mg/mL	Epivir	11/22/2011						
Lamotrigine	Tablets	25 mg, 100 mg, 150 mg and 200 mg	Lamictal 20241							
Lamotrigine	Chewable Tablets	2 mg, 5 mg and 25 mg	Lamictal CD 20764							
Lamotrigine	Orally Disintegrating Tablets	25 mg, 50 mg, 100 mg, and 200 mg	Lamictal ODT 22251	12/21/2009						
Lamotrigine	Extended-release Tablets	25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg	Lamictal XR 22115	2/12/2014						
Lansoprazole	Delayed-release Pellets/Capsules	15 mg and 30 mg	Prevacid 20406	12/05/2005						
Lansoprazole	Delayed-release Orally Disintegrating Tablets	15 mg and 30 mg	Prevacid 21428	12/27/2006						
Lanthanum Carbonate	Chewable Tablet	500 mg, 750 mg and 1000 mg	Fosrenol 21468	10/27/2008	3	Deferred	7/16/2019	8/11/2017	8/30/2017	8/26/2024
Lanthanum Carbonate	Oral Powder	750 mg and 1000 mg	Fosrenol 204734	11/25/2015	1					12/1/2030
Lapatinib Ditosylate	Tablets	250 mg	Tykerb 22059	3/14/2011						
Latanoprost	Ophthalmic Solution	0.005%	Xalatan 20597							
Lenalidomide	Capsules	5 mg, 10 mg and 15 mg	Revlimid 21880	8/30/2010	1					4/22/2026
Lenalidomide	Capsules	25 mg	Revlimid 21880	7/12/2010	1					4/22/2026

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Lenalidomide	Capsules	2.5 mg and 20 mg	Revlimid 21880	7/12/2016						
Lenvatinib	Capsules	4 mg and 10 mg	Lenvima 206947	2/13/2019						
Letrozole	Tablets	2.5 mg	Femara 20726	3/2/2006						
Leuprolide Acetate	Injection (depot)	7.5 mg/vial	Lupron Depot 19732							
Levalbuterol Hydrochloride	Inhalation Solution	0.0103%, 0.021% and 0.042%	Xopenex 20837	6/20/2005						
Levalbuterol Hydrochloride	Inhalation Solution	0.25%	Xopenex 20837	5/23/2006						
Levalbuterol Tartrate*	Inhalation Aerosol	0.045 mg/actuation	Xopenex HFA 21730	2/27/2012						
Levetiracetam	Tablets	250 mg, 500 mg and 750 mg	Keppra 21035							
Levetiracetam	Tablets	1000 mg	Keppra 21035	1/24/2007						
Levetiracetam	Extended-release Tablets	500 mg and 750 mg	Keppra XR 22285	1/7/2011						
Levetiracetam*	Extended-release Tablets	1000 mg	Keppra XR 22285	1/7/2011						
Levocetirizine Dihydrochloride	Oral Solution	0.5 mg/mL	Xyzal 22157	1/14/2009						
Levocetirizine Dihydrochloride	Oral Solution	0.5 mg/mL	Xyzal Allergy 24 HR (OTC) 209090	1/4/2018						
Levocetirizine Dihydrochloride	Tablets	5 mg	Xyzal 22064	12/17/2007						
Levofloxacin	Injection	5 mg/mL; 50 mL, 100 mL and 150 mL vials	Levaquin in Dextrose 5% in Plastic Container 20635							
Levofloxacin	Injection	25 mg/mL	Levaquin 20635							
Levofloxacin	Ophthalmic Solution	0.5%	Quixin 21199							
Levofloxacin	Oral Solution	25 mg/mL	Levaquin 21721	7/30/2009						
Levofloxacin	Tablets	250 mg, 500 mg and 750 mg	Levaquin 20634							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Levoleucovorin Calcium	Injection	10 mg/mL, 17.5 mL vial and 25 mL vial	Fusilev 20140	10/26/2011						
Levoleucovorin Calcium	Injection	50 mg/vial	Fusilev 20140	12/19/2013						
Levomilnacipran	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	Fetzima 204168	7/25/2017						
Levonorgestrel and Ethinyl Estradiol	Tablets	0.09 mg/0.02 mg	Lybrel 21864	10/5/2007						
Levonorgestrel and Ethinyl Estradiol	Tablets	0.15 mg/0.03 mg	Seasonale 21544	3/29/2004						
Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol	Tablets	0.1 mg/0.02 mg and 0.01 mg	LoSeasonique 22262	11/16/2009						
Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol	Tablets	0.15 mg/0.03 mg/0.01 mg	Seasonique 21840	1/22/2008						
Levonorgestrel; Ethinyl Estradiol;Ethinyl Estradiol	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg	Quartette 204061	7/10/2013						
Levothyroxine Sodium	Tablets	0.025 mg, 0.05 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.2 mg and 0.3 mg	Levoxyl 21301							
Levothyroxine Sodium	for Injection	100 mcg/vial and 500 mcg/vial	Levothyroxine Sodium 202231	4/14/2015	2	Eligible	6/18/2019	6/29/2016	4/2/2018	10/3/2032
Levothyroxine Sodium	for Injection	200 mcg/vial	Levothyroxine Sodium 202231	5/1/2015	1	Deferred	6/18/2019	12/7/2015	7/5/2016	10/3/2032
Levothyroxine Sodium	Capsules	75 mcg and 150 mcg	Tirosint 21924	12/29/2017						
Levothyroxine Sodium New	Capsules	88 mcg, 100 mcg and 125 mcg	Tirosint 21924	8/1/2019	1					3/14/2024
Lidocaine	Topical Patch	5%	Lidoderm 20612	11/13/2009						
Linacotide	Capsules	145 mcg and 290 mcg	Linzess 202811	8/30/2016	4					10/30/2031

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Linaclootide	Capsules	72 mcg	Linzess 202811	11/7/2017	1					8/16/2033
Linagliptin	Tablets	5 mg	Tradjenta 201280	5/4/2015	11					6/4/2030
Linagliptin and Metformin Hydrochloride	Tablets	2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg	Jentadueto 201281	5/4/2015	8					6/4/2030
Linagliptin and Metformin Hydrochloride	Extended-release Tablets	2.5 mg/1000 mg 5 mg/1000 mg	Jentadueto XR 208026	3/28/2018	1					
Linezolid	Injection	2 mg/mL, 100 mL bag	Zyvox 21131	12/29/2009						
Linezolid	Injection	2 mg/mL, 300 mL bag	Zyvox 21131	9/1/2009						
Linezolid	Oral Suspension	100 mg/5 mL	Zyvox 21132	8/3/2009						
Linezolid	Tablets	600 mg	Zyvox 21130	12/21/2005						
Liraglutide	Injection	18 mg/3 mL prefilled syringe	Victoza 22341	12/12/2016						
Lisdexamfetamine Dimesylate	Capsules	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg	Vyvanse 21977	2/23/2011						
Loperamide Hydrochloride and Simethicone	Chewable Tablets	2 mg/125 mg	Imodium Multi- Symptom Relief 20606							
Loperamide Hydrochloride and Simethicone	Tablets	2 mg/125 mg	Imodium Multi- Symptom Relief 21140	12/29/2004						
Lopinavir and Ritonavir	Tablets	100 mg/25 mg and 200 mg/50 mg	Kaletra 21906	12/23/2008						
Lopinavir and Ritonavir	Oral Solution	80 mg/20 mg per mL	Kaletra 21251	6/19/2014						
Loratadine	Syrup	1 mg/mL	Claritin 20641							
Loratadine	Tablets	10 mg	Claritin 19658							
Loratadine	Orally Disintegrating Tablets	10 mg	Claritin RediTabs 20704							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Loratadine/ Pseudoephedrine	Extended-release Tablets	5 mg/120 mg	Claritin D-12 hour 19670							
Loratadine/ Pseudoephedrine	Extended-release Tablets	10 mg/240 mg	Claritin D-24 hour 20470							
Lorcaserin Hydrochloride	Extended-release Tablets	20 mg	Belviq XR 208524	12/13/2016						
Lorcaserin Hydrochloride	Tablets	10 mg	Belviq 22529	6/27/2016						
Losartan Potassium	Tablets	25 mg, 50 mg, and 100 mg	Cozaar 20386							
Losartan Potassium and Hydrochlorothiazide	Tablets	50 mg/12.5 mg and 100 mg/25 mg	Hyzaar 20387	5/24/2004						
Losartan Potassium and Hydrochlorothiazide	Tablets	100 mg/12.5 mg	Hyzaar 20387	4/4/2006						
Lovastatin and Niacin	Extended-release Tablets	20 mg/500 mg	Advicor	9/22/2008						
Lovastatin and Niacin	Extended-release Tablets	20 mg/750 mg	Advicor	12/17/2008						
Lovastatin and Niacin	Extended-release Tablets	20 mg/1000 mg	Advicor	5/22/2008						
Lovastatin and Niacin	Extended-release Tablets	40 mg/1000 mg	Advicor	11/19/2009						
Lubiprostone	Capsules	8 mcg and 24 mcg	Amitiza 21908	8/20/2012						
Lurasidone Hydrochloride	Tablets	20 mg, 40 mg, 60 mg, 80 mg, and 120 mg	Latuda 200603	10/28/2014	14	Eligible	8/27/2019	1/3/2019		5/26/2026
Macitentan	Tablets	10 mg	Opsumit 204410	10/18/2017	12					4/18/2029
Malathion	Topical Lotion	0.50%	Ovide 18613	3/16/2011						
Maraviroc	Tablets	150 mg and 300 mg	Selzentry 22128	8/8/2011						
Mefloquine Hydrochloride	Tablets	250 mg	Lariam 19591							
Megestrol Acetate	Oral Suspension	40 mg/mL	Megace 20264							
Megestrol Acetate	Oral Suspension	125 mg/mL	Megace ES 21778	4/27/2011						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Meloxicam *	Oral Suspension	7.5 mg/5 mL	Mobic 21530	12/17/2009						
Meloxicam	Capsules	5 mg and 10 mg	Vivlodex 207233	1/9/2017						
Melphalan Hydrochloride	Injection	50 mg/vial	Evomela 207155	9/8/2017						
Memantine Hydrochloride	Tablets	5 mg and 10 mg	Namenda 21487	10/16/2007						
Memantine Hydrochloride	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	Namenda XR 22525	6/10/2013						
Memantine Hydrochloride Extended-release and Donepezil Hydrochloride	Capsules	14 mg/10 mg and 28 mg/10 mg	Namzaric 206439	5/18/2015						
Memantine Hydrochloride Extended-release and Donepezil Hydrochloride	Capsules	21 mg/10 mg	Namzaric 206439	9/23/2016						
Memantine Hydrochloride Extended-release and Donepezil Hydrochloride	Capsules	7 mg/10 mg	Namzaric 206439	9/26/2016						
Mesalamine*	Delayed-release Tablets	400 mg	Asacol 19651	6/22/2007						
Mesalamine	Delayed-release Tablets	800 mg	Asacol HD 21830	7/13/2011						
Mesalamine	Delayed-release Tablets	1.2 g	Lialda 22000	12/16/2009						
Mesalamine*	Extended-release Capsules	0.375 g	Apriso 22301	4/3/2012	1					4/20/2018
Mesalamine	Suppository	1000 mg	Canasa 21252	5/24/2013	1	Eligible	8/27/2019	11/24/2015	11/24/2015	6/6/2028
Mesalamine	Delayed-release Capsules	400 mg	Delzicol 204412	6/17/2014	1	Extinguished Non Forfeiture	6/18/2019 6/18/2019			4/13/2020
Metaxalone	Tablets	400 mg	Skelaxin 13217							
Metaxalone	Tablets	800 mg	Skelaxin 13217	11/4/2004						
Metformin Hydrochloride	Extended-release Tablets	500 mg	Glucophage XR 21202							
Metformin Hydrochloride	Extended-release Tablets	750 mg	Glucophage XR 21202							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Metformin Hydrochloride	Extended-release Tablets	500 mg and 1000 mg	Fortamet 21574	10/14/2008						
Metformin Hydrochloride	Extended-release Tablets	500 mg and 1000 mg	Glumetza 21748	7/27/2009	1	Eligible	7/16/2019	7/19/2013	2/1/2016	500mg:10/25/2021 1 g: 6/20/2020
Metformin Hydrochloride	Oral Solution	500 mg/5 mL	Riomet 21591	2/2/2018						
Methylnaltrexone Bromide	Injection	12 mg/0.6 mL	Relistor 21964	7/22/2015	1					12/31/2030
Methylnaltrexone Bromide	Injection	8 mg/0.4 mL	Relistor 21964	9/8/2015	1					12/31/2030
Methylnaltrexone Bromide	Tablets	150 mg	Relistor 208271	9/6/2016						
Methylphenidate Hydrochloride*	Extended-release Capsules	10 mg	Ritalin LA 21284	5/21/2007						
Methylphenidate Hydrochloride	Extended-release Capsules	20 mg, 30 mg and 40 mg	Ritalin LA 21284	8/21/2006						
Methylphenidate Hydrochloride	Extended-release Capsules	10 mg, 20 mg and 30 mg	Metadate CD 21259	5/13/2005						
Methylphenidate Hydrochloride	Extended-release Capsules	40 mg	Metadate CD 21259	3/15/2007						
Methylphenidate Hydrochloride	Extended-release Chewable Tablets	20 mg, 30 mg and 40 mg	Quilchew ER 207960	4/25/2016						
Methylphenidate Hydrochloride	Extended-release Tablets	18 mg*, 27 mg, 36 mg and 54 mg	Concerta 21121	7/19/2005						
Methylphenidate Hydrochloride	Oral Solution	5 mg/5 mL 10 mg/5 mL	Methylin 21419	4/13/2010						
Methylphenidate	Transdermal System	10 mg/9 hrs 15 mg/9 hrs 20 mg/9 hrs 30 mg/9 hrs	Daytrana 21514	4/13/2011						
Methylphenidate Hydrochloride	Extended-release Oral Suspension	5 mg/mL	Quillivant XR 202100	8/2/2013						
Methylphenidate Hydrochloride	Extended-release Capsules	60 mg	Aptensio XR 205831	12/23/2015	1	Eligible	7/30/2019	12/13/2018		12/16/2019
Methylphenidate Hydrochloride	Extended-release Capsules	10 mg	Aptensio XR 205831	12/24/2015	1	Eligible	7/30/2019	12/13/2018		12/16/2019
Methylphenidate Hydrochloride	Extended-release Capsules	15 mg, 20 mg, 40 mg and 50 mg	Aptensio XR 205831	12/28/2015	1	Eligible	7/30/2019	12/13/2018		12/16/2019

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Methylphenidate Hydrochloride	Extended-release Capsules	30 mg	Aptensio XR 205831	3/28/2016	1	Eligible	7/30/2019	12/13/2018		12/16/2019
Methylphenidate	Extended-release Orally Disintegrating Tablets	8.6 mg, 17.3 mg and 25.9 mg	Cotempla XR-ODT 205489	9/1/2017						
Metoclopramide Hydrochloride	Injection	5 mg/mL, 2 mL, 10 mL, 20 mL and 30 mL vials	Reglan 17862							
Metoclopramide Hydrochloride	Orally Disintegrating Tablets	5 mg and 10 mg	Metozolv ODT 22246	8/24/2010						
Metoprolol Succinate	Extended-release Tablets	25 mg, 50 mg, 100 mg and 200 mg	Toprol XL 19962							
Metronidazole	Vaginal Gel	0.75%	MetroGel-Vaginal 20208	9/2/2004						
Metronidazole	Topical Gel	1%	Metrogel 21789	10/21/2008						
Micafungin Sodium	For Injection	50 mg/vial 100 mg/vial	Mycamine 21506	6/16/2014						
Miconazole Nitrate	Vaginal Cream and Suppository	2% and 1.2 g	Monistat 1 Combination Pack 21308	12/5/2007						
Mifepristone	Tablets	300 mg	Korlym 202107	12/15/2017						
Milnacipran Hydrochloride	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	Savella 22256	1/14/2013						
Minocycline Hydrochloride	Extended-release Tablet	45 mg, 90 mg and 135 mg	Solodyn 50808	PIV received prior to 2/5/2009						
Minocycline Hydrochloride	Extended-release Tablet	55 mg	Solodyn 50808	12/2/2010						
Minocycline Hydrochloride	Extended-release Tablet	65 mg and 115 mg	Solodyn 50808	11/19/2009	1	Extinguished Eligible	6/18/2019 6/18/2019	5/18/2012	2/20/2018	2/19/2018
Minocycline Hydrochloride	Extended-release Tablet	80 mg	Solodyn 50808	10/27/2010						
Minocycline Hydrochloride	Extended-release Tablet	105 mg	Solodyn 50808	12/13/2010						
Minoxidil	Topical Aerosol Foam	5%	Men's Rogaine 21812	4/6/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Mirabegron	Extended-release Tablets	25 mg and 50 mg	Myrbetriq 202611	6/28/2016	7					11/4/2023
Mirtazapine	Tablets	7.5 mg, 15 mg, 30 mg, and 45 mg	Remeron 20415							
Mirtazapine	Orally Disintegrating Tablets	15 mg, 30 mg and 45 mg	Remeron SolTab 21208							
Modafinil	Tablets	100 mg and 200 mg	Provigil 20717							
Moexipril Hydrochloride	Tablets	7.5 mg and 15 mg	Univasc 20312							
Moexipril Hydrochloride and Hydrochlorothiazide	Tablets	7.5mg/12.5mg, 15 mg/25 mg and 15 mg/12.5 mg	Uniretic 20729	1/15/2004						
Mometasone Furoate	Nasal Spray	50 mcg/ Spray	Nasonex 20762	8/7/2009						
Mometasone Furoate	Topical Solution (Cream)	0.1%	Elocon 19625							
Mometasone Furoate	Topical Solution (Lotion)	0.1%	Elocon 19796	6/10/2004						
Montelukast	Tablets	10 mg	Singulair 20829	2/20/2007						
Montelukast Sodium	Chewable Tablets	4 mg and 5 mg	Singulair 20830	12/26/2006						
Montelukast Sodium	Oral Granules	4 mg	Singular Granules 21409	10/17/2008						
Morphine Sulfate	Extended-release Capsules	30 mg, 60 mg, 90 mg and 120 mg	Avinza 21260	6/4/2007						
Morphine Sulfate*	Extended-release Capsules	45 mg and 75 mg	Avinza 21260	7/30/2009						
Morphine Sulfate	Extended-release Tablets	15 mg, 30 mg and 60 mg	Arymo ER 208603	12/29/2017						
Morphine Sulfate	Extended-release Tablets	15 mg, 30 mg, 60 mg and 100 mg	Morphabond ER 206544	1/28/2019						
Morphine Sulfate and Naltrexone Hydrochloride	Extended-release Capsules	20 mg/0.8 mg	Embeda 22321	8/16/2018						
Morphine Sulfate and Naltrexone Hydrochloride	Extended-release Capsules	100 mg/4 mg	Embeda 22321	5/3/2010						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Morphine Sulfate and Naltrexone Hydrochloride	Extended-release Capsules	60 mg/2.4 mg	Embeda 22321	5/25/2010						
Morphine Sulfate and Naltrexone Hydrochloride	Extended-release Capsules	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	Embeda 22321	5/28/2010						
Moxifloxacin Hydrochloride*	Ophthalmic Solution/Drops	0.5%	Vigamox 21598	12/22/2005						
Moxifloxacin Hydrochloride	Ophthalmic Solution	0.5%	Moxeza 22428	2/29/2012						
Moxifloxacin Hydrochloride	Tablets	400 mg	Avelox 21085							
Moxifloxacin Hydrochloride	Injection	1.6 mg/mL	Avelox in Sodium Chloride 0.8% in plastic container 21277	2/7/2014	1	Deferred		5/5/2017	10/3/2017	7/25/2020
Mycophenolic Acid	Delayed-release Tablets	180 mg	Myfortic 50791	6/3/2009						
Mycophenolic Acid	Delayed-release Tablets	360 mg	Myfortic 50791	2/2/2009						
Mycophenolic Mofetil	For Oral Suspension	200 mg/mL	Cellcept 50759	3/25/2011						
Nabumetone	Tablets	500 mg and 750 mg	Relafen 19583							
Naftifine Hydrochloride	Gel	2%	Naftin Gel 204286	2/4/2015	1	Deferred	8/13/2019	4/10/2019		1/31/2033
Naloxegol	Tablets	12.5 mg and 25 mg	Movantik 204760	9/17/2018						
Naloxone Hydrochloride	Nasal Spray	2 mg/spray	Narcan 208411	12/28/2017	1					3/16/2035
Naloxone Hydrochloride	Nasal Spray	4 mg/spray	Narcan 208411	7/15/2016	1	Eligible	6/18/2019	4/19/2019		3/16/2035
Naltrexone Hydrochloride and Bupropion Hydrochloride	Extended-release Tablets	8 mg/90 mg	Contrave 200063	3/12/2015						
Naproxen Sodium	Extended-release Tablets	375 mg (base) and 500 mg (base)	Naprelan 20353							
Naproxen Sodium	Capsules	200 mg	Naproxen Sodium 21920	11/15/2017						
Naproxen and Esomeprazole Magnesium	Delayed-release Tablets	375 mg/20 mg and 500 mg/20 mg	Vimovo 22511	11/5/2010						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Naproxen Sodium and Sumatriptan Succinate *	Tablets	500 mg/85 mg	Treximet 21926	7/23/2008						
Nateglinide	Tablets	60 mg and 120 mg	Starlix 21204	12/22/2004						
Nebivolol Hydrochloride	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	Bystolic 21742	12/19/2011	7	Eligible	6/18/2019	4/16/2015		12/17/2021
Nebivolol Hydrochloride and Valsartan	Tablets	5 mg/80 mg	Byvalson 206302	6/9/2017						
Nefazodone Hydrochloride	Tablets	50 mg, 100 mg, 150 mg, 200 mg and 250 mg	Serzone 20152							
Nepafenac	Ophthalmic Suspension	0.3%	Ilevro 203491	12/21/2015	1					3/31/2032
Nevirapine	Extended-release Tablets	400 mg	Viramune XR 201152	6/21/2013						
Niacin	Extended-release Tablets	500 mg, 750 mg and 1000 mg	Niaspan 20381							
Niacin and Simvastatin	Extended-release Tablets	500 mg/20 mg	Simcor	2/12/2010						
Niacin and Simvastatin	Extended-release Tablets	750 mg/20 mg	Simcor	2/17/2010						
Niacin and Simvastatin	Extended-release Tablets	1000 mg/20 mg	Simcor	9/17/2009						
Niacin and Simvastatin	Extended-release Tablets	1000 mg/40 mg	Simcor	2/4/2011						
Niacin and Simvastatin	Extended-release Tablets	500 mg/40 mg	Simcor	2/9/2011						
Nicardipine Hydrochloride	Injection	2.5 mg/mL, 10 mL Ampoules	Cardene 19734	12/27/2006						
Nicardipine Hydrochloride	Injection	0.1 mg/mL, 200 mL 0.2mg/mL, 200 mL	Cardene in 0.86% Sodium Chloride in plastic container and Cardene 0.83% Sodium Chloride in plastic container 19734	1/9/2013						
Nicotine	Transdermal System	7 mg/day, 14 mg/day 21 mg/day	Habitrol 20076							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Nicotine	Transdermal System	7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs	Nicoderm CQ 20165	5/30/2014						
Nicotine Polacrilex	Troche/Lozenge	2 mg and 4 mg	Commit							
Nicotine Polacrilex	Troche/Lozenge (Mini)	2 mg and 4 mg	Nicorette 22360	12/2/2015	1	Eligible		2/7/2019	4/4/2019	6/14/2029
Nicotine Polacrilex	Gum	2 mg	Nicorette	1/22/2013						
Nicotine Polacrilex	Gum	4 mg	Nicorette	1/22/2013						
Nifedipine	Capsules	10 mg and 20 mg	Procardia 18482							
Nifedipine	Extended-release Tablets	30 mg, 60 mg and 90 mg	Adalat CC 20198							
Nifedipine	Extended-release Tablets	30 mg, 60 mg and 90 mg	Procardia XL 19684							
Nilotinib	Capsules	150 mg and 200 mg	Tasigna 22068	11/8/2013						
Nintedanib	Capsules	100 mg and 150 mg	Ofev 205832	10/15/2018						
Nitric Oxide	for Inhalation	100 ppm and 800 ppm	INOMax 20845	5/20/2014						
Nisoldipine	Extended-release Tablets	8.5 mg and 17 mg	Sular 20356	3/2/2009						
Nisoldipine	Extended-release Tablets	20 mg and 30 mg	Sular 20356	11/7/2007						
Nisoldipine	Extended-release Tablets	25.5 mg and 34 mg	Sular 20356	11/28/2008						
Nisoldipine	Extended-release Tablets	40 mg	Sular 20356	6/11/2007						
Nitrofurantoin Monohydrate/ Macrocrystals	Capsules	75 mg/25 mg	Macrobid 20064							
Nitroglycerin*	Sublingual Tablets	0.3 mg, 0.4 mg, and 0.6 mg	Nitrostat 21134	10/19/2005						
Nitroglycerin	Transdermal System	0.1 mg/hr	Transderm-Nitro 20144							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Nitroglycerin	Transdermal System	1.1 mg/hr 1.2 mg/hr 1.3 mg/hr 1.4 mg/hr 0.6 mg/hr 0.8 mg/hr	Nitro-dur 20145							
Nitroglycerin	Sublingual Spray	400 mcg/spray, 4.9 g and 12 g bottles	Nitrolingual Pumpspray 18705	4/17/2012						
Nizatidine	Capsules	150 mg and 300 mg	Axid 19508							
Nizatidine	Oral Solution	15 mg/mL	Axid 21494	5/14/2008						
Norelgestromin and Ethinyl Estradiol*	Transdermal System	0.15 mg/0.02 mg per 24 hours	Ortho Evra 21180	3/22/2007						
Norethindrone Acetate/ Ethinyl Estradiol	Tablets	1 mg/0.005 mg	Femhrt 21065							
Norethindrone Acetate/ Ethinyl Estradiol	Tablets	1 mg/ 0.02 mg 1 mg/0.03 mg 1 mg /0.035 mg	Estrostep Fe 20130							
Norethindrone Acetate/ Ethinyl Estradiol	Tablets	1 mg/0.02 mg 1 mg/ 0.03 mg and 1 mg /0.035 mg	Estrostep 21 20130							
Norethindrone Acetate/ Ethinyl Estradiol and Ferrous Fumarate	Tablets	1 mg/0.02 mg and 75 mg	Loestrin 24 Fe 21871	4/17/2006						
Norethindrone Acetate and Ethinyl Estradiol / Ethinyl Estradiol and Ferrous Fumarate	Tablets	1 mg/0.01 mg, 0.01 mg and 75 mg	Lo Loestrin Fe 22501	4/29/2011						
Norethindrone and Ethinyl Estradiol and Ferrous Fumarate	Chewable Tablets	0.4 mg/0.035 mg	Ovcon-35 Fe Femcon Fe NDA 21-490	4/27/2007						
Norethindrone and Ethinyl Estradiol and Ferrous Fumarate	Chewable Tablets	0.8 mg/0.025 mg and 75 mg	Generess Fe	8/5/2011						
Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate	Chewable Tablets	1 mg/0.02 mg and 75 mg	Minastrin 24 Fe 203667	4/23/2014						
Norethindrone/ Ethinyl Estradiol	Tablets	0.5 mg/ 0.035 mg, 0.75 mg/ 0.035 mg and 1 mg /0.035 mg	Ortho-Novum 7/7/7, 21 and 28 day 18985							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Norgestimate/ Ethinyl Estradiol	Tablets	0.18 mg /0.025 mg, 0.215 mg /0.025 mg and 0.25 mg /0.025 mg	Ortho Tri-Cyclen Lo, 28 day 21241							
Norgestimate/ Ethinyl Estradiol	Tablets	0.18 mg /0.035 mg, 0.215 mg /0.035 mg and 0.25 mg /0.035 mg	Ortho Tri-Cyclen, 21 and 28 day 19697							
Nortriptyline Hydrochloride	Capsules	10 mg, 25 mg, 50 mg and 75 mg	Pamelor 18013							
Octreotide Acetate	Injection	0.05 mg /mL, 0.1 mg /mL and 0.5 mg/mL, 1 mL vials	Sandostatin (Preservative-free) 19667							
Octreotide Acetate	Injection	0.2 mg/mL and 1 mg /mL, 5 mL vials	Sandostatin 19667							
Octreotide Acetate	Injection	0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free)	Octreotide Acetate Injection 19667	1/17/2008						
Ofloxacin	Otic Solution	0.3%	Floxin 20799							
Olanzapine	Tablets	2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg	Zyprexa 20592							
Olanzapine	Tablets	20 mg	Zyprexa 20592							
Olanzapine	Orally Disintegrating Tablets	5 mg, 10 mg, 15 mg and 20 mg	Zyprexa Zydis 21086							
Olanzapine and Fluoxetine Hydrochloride	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, 12 mg/50 mg	Symbyax 21520	1/10/2005						
Olmesartan Medoxomil	Tablets	5 mg, 20 mg and 40 mg	Benicar 21286	4/25/2006						
Olmesartan Medoxomil and Hydrochlorothiazide	Tablets	20 mg/12.5 mg	Benicar HCT 21532	5/11/2007						

**Paragraph IV Patent Certifications
September 23, 2019**

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Olmesartan Medoxomil and Hydrochlorothiazide	Tablets	40 mg/12.5 mg and 40 mg/25 mg	Benicar HCT 21532	2/15/2007						
Olopatadine Hydrochloride	Nasal Spray	0.665 mg/ Spray	Patanase 21861	6/29/2009						
Olopatadine Hydrochloride	Ophthalmic Solution	0.1%	Patanol 20688	7/17/2006						
Olopatadine Hydrochloride	Ophthalmic Solution	0.2%	Pataday 21545	9/8/2008	1	Eligible	6/18/2019	7/13/2015	6/8/2017	11/12/2023
Olopatadine Hydrochloride	Ophthalmic Solution	0.7%	Pazeo 206276	9/10/2015	1	Non-forfeiture	6/18/2019			5/19/2032
Omacetaxine Mepesuccinate	for Injection	3.5 mg/vial	Synribo 203585	10/26/2016						
Omega-3-Acid Ethyl Esters	Capsules	1 g	Lovaza 21654	11/10/2008						
Omeprazole	Delayed-release Capsules	10 mg, 20 mg and 40 mg	Prilosec 19810							
Omeprazole and Sodium Bicarbonate	Capsules	20 mg/1100 mg and 40 mg/1100 mg	Zegerid 21849	4/30/2007						
Omeprazole and Sodium Bicarbonate	Capsules	20 mg/1100 mg	Zegerid OTC 22281	4/20/2010						
Omeprazole and Sodium Bicarbonate	Powder for Oral Suspension	20mg/1680mg per packet	Zegerid 21636	11/13/2007						
Omeprazole and Sodium Bicarbonate	Powder for Oral Suspension	40 mg/1680 mg per packet	Zegerid 21636	8/24/2007						
Omeprazole Magnesium	Delayed-release Capsules	20 mg	Prilosec OTC 21229	3/19/2007						
Omeprazole Magnesium	Delayed-release Tablets	20 mg	Prilosec OTC 21229	3/30/2012						
Omeprazole	Delayed-release Tablets	20 mg	Omeprazole 22032 (OTC)	6/3/2015						
Ondansetron Hydrochloride	Injection	2 mg/mL, 2 mL vials (Preservative-free)	Zofran 20007							
Ondansetron Hydrochloride	Injection	2 mg/mL, 20 mL vials	Zofran 20007							
Ondansetron Hydrochloride	Injection	0.64 mg/mL, 50 mL container (plastic)	Zofran in Plastic Container 20403							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Ondansetron Hydrochloride	Oral Solution	4 mg/5 mL	Zofran 20605	12/20/2004						
Ondansetron Hydrochloride	Orally Disintegrating Tablets	4 mg and 8 mg	Zofran ODT 20781							
Ondansetron Hydrochloride	Tablets	4 mg, 8 mg, 16 mg and 24 mg	Zofran 20103							
Orlistat	Capsules	60 mg	Alli 21887	9/8/2010						
Oseltamivir Phosphate	Capsules	30 mg and 45 mg	Tamiflu 21087	8/2/2011						
Oseltamivir Phosphate	Capsules	75 mg	Tamiflu 21087	11/15/2010						
Oseltamivir Phosphate	for Oral Suspension	6 mg/mL	Tamiflu 21246	6/18/2015						
Oxaliplatin	For Injection	50 mg/vial and 100 mg/vial	Eloxatin 21492	2/9/2007						
Oxaliplatin	Injection	5 mg/mL, 10 mL and 20 mL vials	Eloxatin 21759	2/9/2007						
Oxaliplatin *	Injection	5 mg/mL, 40 mL vials	Eloxatin 21759	7/16/2007						
Oxandrolone	Tablets	2.5 mg and 10 mg	Oxandrin 13718	6/19/2006						
Oxazepam	Capsules	10 mg, 15 mg and 30 mg	Serax 15539							
Oxcarbazepine	Tablets	150 mg, 300 mg and 600 mg	Trileptal 21014	5/5/2006						
Oxcarbazepine	Oral Suspension	300 mg/5 mL	Trileptal 21285	12/26/2006						
Oxcarbazepine*	Extended-release Tablets	600 mg	Oxtellar XR 202810	3/20/2013						
Oxcarbazepine*	Extended-release Tablets	150 mg and 300 mg	Oxtellar XR 202810	4/12/2013						
Oxybutynin	Transdermal System Extended-release	3.9 mg/24 hrs	Oxytrol 21351	8/19/2008						
Oxybutynin Chloride	Extended-release Tablets	5 mg, 10 mg and 15 mg	Ditropan XL 20897							
Oxybutynin Chloride	Gel	10%	Gelnique 22204	6/19/2014	1	Deferred	6/18/2019	5/31/2018		4/26/2020

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Oxycodone	Extended-release Tablets	10 mg, 20 mg, 40 mg, 80 mg and 160 mg	Oxycontin (NDA 020553)							
Oxycodone Hydrochloride	Extended-release Tablets	15 mg	Oxycontin (NDA 020553)	2/15/2007						
Oxycodone Hydrochloride	Extended-release Tablets	30 mg and 60 mg	Oxycontin (NDA 020553)	1/3/2007						
Oxycodone Hydrochloride	Extended-release Tablets	10 mg	Oxycontin (NDA 022272)	10/25/2010	1					4/19/2025
Oxycodone Hydrochloride	Extended-release Tablets	15 mg	Oxycontin (NDA 022272)	10/28/2010	1					4/19/2025
Oxycodone Hydrochloride	Extended-release Tablets	20 mg	Oxycontin (NDA 022272)	10/29/2010	2					4/19/2025
Oxycodone Hydrochloride*	Extended-release Tablets	30 mg, 60 mg and 80 mg	Oxycontin (NDA 022272)	10/18/2010	1	Extinguished	6/18/2019			4/19/2025
Oxycodone Hydrochloride	Extended-release Tablets	40 mg	Oxycontin (NDA 022272)	10/4/2010	1					4/19/2025
Oxycodone Hydrochloride	Tablets	5 mg and 7.5 mg	Oxecta	2/7/2012						
Oxycodone	Extended-release Capsules	9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg	Xtampza ER 208090	11/15/2017						
Oxycodone Hydrochloride and Acetaminophen	Extended-release Tablets	7.5 mg/325 mg	Xartemis XR	4/3/2014						
Oxymetazoline Hydrochloride	Topical Cream	1%	Rhofade 208552	6/20/2019	1					6/11/2035
Oxymorphone Hydrochloride	Extended-release Tablets	5 mg, 10 mg, 20 mg and 40 mg	Opana ER	11/23/2007						
Oxymorphone Hydrochloride	Extended-release Tablets	7.5 mg and 15 mg	Opana ER	5/29/2008						
Oxymorphone Hydrochloride	Extended-release Tablets	30 mg	Opana ER	6/12/2008						
Oxymorphone Hydrochloride*	Extended-release Tablets	7.5 mg, 10 mg, and 15 mg	Opana ER (NDA 201655)	3/23/2012						
Oxymorphone Hydrochloride	Extended-release Tablets	5 mg	Opana ER (NDA 201655)	3/26/2012						
Oxymorphone Hydrochloride	Extended-release Tablets	20 mg, 30 mg and 40 mg	Opana ER (NDA 201655)	4/3/2012						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Paclitaxel	Injection	6 mg/mL, 5 mL, 16.7 mL, 25 mL, 33.3 mL and 50 mL vials	Taxol 20262							
Paclitaxel Protein-Bound Particles	For Injection Suspension	100 mg/vial	Abraxane 21660	12/11/2015	1					10/27/2024
Palbociclib	Capsules	75 mg, 100 mg and 125 mg	Ibrance 207103	2/4/2019						
Paliperidone Palmitate	Extended-release Injectable Suspension	39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	Invega Sustenna 22264	11/21/2017						
Palonosetron Hydrochloride	Injection	0.05 mg/mL, 1.5 mL and 5 mL vials	Aloxi 21372	5/27/2011						
Pamidronate Disodium	For Injection	30 mg/vial 60 mg/vial 90 mg/vial	Aredia 20036							
Pamidronate Disodium	Injection	30 mg/vial 60 mg/vial 90 mg/vial	Aredia 20036							
Pantoprazole Sodium	For Injection	40 mg/vial	Prontonix IV 20988	4/7/2005	1	Extinguished	8/27/2019			11/17/2021
Pantoprazole Sodium	Delayed-release Tablets	20 mg and 40 mg	Protonix 20987	2/2/2004						
Paricalcitol*	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	Zemplar 20819	11/28/2008						
Paricalcitol	Capsules	1 mcg and 2 mcg	Zemplar 21606	10/14/2008						
Paricalcitol	Capsules	4 mcg	Zemplar 21606	8/25/2008						
Paroxetine Hydrochloride	Capsules	10 mg and 20 mg	Paxil 20885							
Paroxetine Hydrochloride	Oral Suspension	10 mg/5 mL	Paxil 20710	2/10/2005						
Paroxetine Hydrochloride	Tablets	10 mg, 20 mg, 30 mg and 40 mg	Paxil 20031							
Paroxetine Hydrochloride	Extended-release Tablets	25 mg	Paxil CR 20936	9/9/2005						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Paroxetine Hydrochloride	Extended-release Tablets	37.5 mg	Paxil CR 20936	5/19/2009						
Paroxetine	Capsules	7.5 mg	Brisdelle 204516	4/7/2014	1	Extinguished	8/13/2019	3/13/2019		4/6/2029
Pemetrexed Disodium *	For Injection	100 mg/vial	Alimta 21462	7/1/2008						
Pemetrexed Disodium *	For Injection	500 mg/vial	Alimta 21462	2/4/2008						
Pemetrexed Disodium *	For Injection	1000 mg/vial	Alimta 21462	6/27/2012						
Pemetrexed Disodium	For Injection	750 mg/vial	Alimta 21462	10/6/2016						
Perampanel	Tablets	2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg	Fycompa 202834	10/24/2016						
Pergolide Mesylate	Tablets	0.05 mg, 0.25 mg and 1 mg	Permax 19385							
Perindopril Arginine and Amlodipine	Tablets	3.5 mg/2.5 mg, 7 mg/5 mg and 14 mg/10 mg	Prestalia 205003	11/4/2016						
Perindopril Erbumine	Tablets	2 mg, 4 mg and 8 mg	Aceon 20184	6/6/2006						
Phentermine Hydrochloride	Orally Disintegrating Tablets	15 mg and 30 mg	Suprenza 202088	10/19/2012						
Phentermine Hydrochloride	Orally Disintegrating Tablets	37.5 mg	Suprenza 202088	3/22/2013						
Phentermine Hydrochloride and Topiramate	Extended-release Capsules	3.75 mg/23 mg 7.5 mg/46 mg 11.25 mg/69 mg 15 mg/92 mg	Qsymia 22580	7/18/2013						
Phenylephrine and Ketorolac	Injection	1%/0.3%	Omidria 205388	5/29/2015	1	Extinguished	8/13/2019			7/30/2023
Pioglitazone Hydrochloride	Tablets	15 mg, 30 mg and 45 mg	Actos 21073							
Pioglitazone Hydrochloride and Glimperide	Tablets	30 mg/2 mg and 30 mg/4 mg	Duetact 21925	12/22/2009						
Pioglitazone Hydrochloride and Metformin Hydrochloride	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg	Actoplus Met XR 22024	9/23/2011						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Pioglitazone Hydrochloride and Metformin Hydrochloride	Tablets	15 mg/500 mg and 15 mg/850 mg	Actoplus Met 21824	3/6/2008						
Piperacillin Sodium and Tazobactam Sodium	For Injection	2.25 g/vial 3.375 g/vial 4.5 g/vial	Zosyn 50684	PIV received prior to 2/5/2009						
Piperacillin Sodium and Tazobactam Sodium	For Injection	12 g/1.5 g per vial (pharmacy bulk)	Zosyn 50684	12/6/2011						
Pirfenidone	Capsules	267 mg	Esbriet 22535	10/15/2018						
Pirfenidone	Tablets	267 mg, 534 mg and 801 mg	Esbriet 208780	10/15/2018						
Pitavastatin Calcium	Tablets	1 mg, 2 mg, and 4 mg	Livalo 22363	8/5/2013						
Plerixafor	Injection	24 mg/1.2 mL vials (20 mg/mL)	Mozobil 22311	12/17/2012						
Polyethylene Glycol 3350	Powder for Oral Solution	17g/Scoopful	Miralax 22015							
Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride and Bisacodyl	For Oral Solution and Delayed-release Tablet	210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen)	Halflytely and Bisacodyl	7/30/2010						
Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride and Bisacodyl	For Oral Solution and Delayed-release Tablets	210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (2 Tablet Regimen)	Halflytely and Bisacodyl	1/28/2008						
Polyethylene Glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid	For Oral Solution	100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch	Moviprep 21881	11/27/2007						
Polyethylene Glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, Sodium Sulfate and Ascorbic Acid	For Oral Solution	140 g, 5.2 g, 2.2.g, 48.11 g, 9 g and 7.54 g per pouch	Plenvu 209381	12/6/2018						
Pomalidomide	Capsules	1 mg, 2 mg, 3 mg and 4 mg	Pomalyst 204026	2/8/2017						
Posaconazole	Oral Suspension	40 mg/mL	Noxafil 22003	2/28/2011	1	Extinguished	7/30/2019			7/19/2019

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Posaconazole	Delayed-release Tablets	100 mg	Noxafil 205053	6/16/2014	1	Extinguished	7/30/2019			7/19/2019
Posaconazole	Injection	18 mg/mL, 16.7 mL vials	Noxafil 205596	11/24/2015	1	Eligible	7/30/2019			7/4/2031
Potassium Chloride	Extended-release Capsules	8 mEq and 10 mEq	Micro K							
Potassium Chloride	Extended-release Tablets	10 mEq and 20 mEq	K-Dur							
Pralatrexate	Injection	20 mg/mL and 40 mg/2 mL	Folotyn 22468	9/24/2013						
Pramipexole Dihydrochloride	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg	Mirapex 20667	6/24/2005						
Pramipexole Dihydrochloride	Tablets	0.25 mg	Mirapex 20667	5/27/2005						
Pramipexole Dihydrochloride	Tablets	0.75 mg	Mirapex 20667	7/31/2008						
Pramipexole Dihydrochloride	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg	Mirapex ER 22421	6/1/2010						
Pramipexole Dihydrochloride	Extended-release Tablets	2.25 mg and 3.75 mg	Mirapex ER 22421	7/26/2011						
Prasugrel Hydrochloride	Tablets	5 mg and 10 mg	Effient 22307	7/10/2013						
Pravastatin Sodium	Tablets	10 mg, 20 mg, 40 mg and 80 mg	Pravachol 19898							
Pravastatin Sodium	Tablets	30 mg	Pravachol 19898	6/1/2005						
Prazosin Hydrochloride	Capsules	1 mg, 2 mg and 5 mg	Minipress 17442							
Prednisolone Sodium Phosphate	Oral Solution	5 mg(base)/ 5 mL and 15 mg (base)/ 5 mL	Pediapred 19157							
Prednisolone Sodium Phosphate	Orally Disintegrating Tablets	10 mg, 15 mg and 30 mg	Orapred 21959	7/22/2010	1	Eligible	8/27/2019	4/10/2013	12/8/2014	11/24/2019
Prednisone	Delayed-release Tablets	1 mg, 2 mg, and 5 mg	Rayos 202020	11/26/2012						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Pregabalin	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	Lyrica 21446	12/30/2008						
Pregablin	Oral Solution	20 mg/mL	Lyrica 22488	5/19/2010						
Pregabalin	Extended-release Tablets	330 mg	Lyrica CR 209501	1/29/2018						
Pregabalin	Extended-release Tablets	82.5 mg and 165 mg	Lyrica CR 209501	2/2/2018						
Propafenone	Extended-release Capsules	325 mg	Rythmol SR 21416	11/07/2006						
Propafenone Hydrochloride	Extended-release Capsules	225 mg and 425 mg	Rythmol SR 21416	10/11/2006						
Propofol	Injection	10 mg/mL ; 20 mL, 50 mL and 100 mL vials and 20 mL syringe	Diprivan 19627							
Propranolol Hydrochloride	Extended-release Capsules	60 mg, 80 mg, 120 mg and 160 mg	Inderal LA 18553							
Quetiapine Fumarate	Extended-release Tablets	400 mg	Seroquel XR 22047	6/18/2008						
Quetiapine Fumarate	Extended-release Tablets	150 mg	Seroquel XR 22047	11/17/2008						
Quetiapine Fumarate	Extended-release Tablets	200 mg and 300 mg	Seroquel XR 22047	6/12/2008						
Quetiapine Fumarate	Extended-release Tablets	50 mg	Seroquel XR 22047	10/17/2008						
Quetiapine Fumarate	Tablets	25 mg	Seroquel 20639	8/12/2005						
Quetiapine Fumarate	Tablets	50 mg, 150 mg and 400 mg	Seroquel 20639	2/12/2007						
Quetiapine Fumarate	Tablets	100 mg, 200 mg and 300 mg	Seroquel 20639	2/21/2006						
Quinapril Hydrochloride	Tablets	5 mg, 10 mg, 20 mg and 40 mg	Accupril 19885							
Quinapril Hydrochloride/ Hydrochlorothiazide	Tablets	10 mg/12.5 mg 20 mg/12.5 mg 20mg/25 mg	Accuretic 20125							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Rabeprazole Sodium	Delayed-release Tablets	20 mg	Aciphex 20973							
Raltegravir	Tablets	400 mg	Isentress 22145	10/12/2011						
Raloxifene Hydrochloride	Tablets	60 mg	Evista 20815							
Ramelteon	Tablets	8 mg	Rozerem 21782	7/22/2009	2	Deferred	6/18/2019	7/26/2013		7/22/2019
Ramipril	Capsules	1.25 mg, 2.5 mg, 5 mg and 10 mg	Altace 19901							
Ranitidine	Capsules	150 mg and 300 mg	Zantac							
Ranitidine	Injection	25 mg/mL, 2 mL and 6 mL and 40 mL vials	Zantac							
Ranitidine	Oral Solution	15 mg/mL	Zantac							
Ranitidine	Tablets	75 mg, 150 mg and 300 mg	Zantac							
Ranitidine Hydrochloride	Tablets	150 mg	Zantac 150 (NDA 21698/Product 002)	10/30/2007						
Ranolazine	Extended-release	500 mg and 1000 mg	Renexa 21526	5/17/2010						
Rasagiline Mesylate	Tablets	0.5 mg and 1 mg	Azilect 21461	5/17/2010						
Regadenoson	Injection	0.08 mg/mL, 5 mL vial	Lexiscan 22161	4/10/2012	1	Extinguished	7/2/2019			6/22/2019
Regorafenib	Tablets	40 mg	Stivarga 203085	9/27/2016						
Remifentanyl Hydrochloride	for Injection	1 mg/vial, 2 mg/vial and 5 mg/vial	Ultiva 20630	12/27/2013	1	Extinguished	7/2/2019	1/16/2018	1/26/2018	9/10/2017
Repaglinide	Tablets	0.5 mg*, 1 mg and 2 mg	Prandin 20741	2/10/2005						
Repaglinide and Metformin Hydrochloride*	Tablets	1 mg/500 mg and 2 mg/500 mg	Prandimet 22386	4/9/2009						
Ribavirin	Capsules	200 mg	Rebetol 20903							
Ribavirin	for Inhalation Solution	6 gm/vial	Virazole 18859	5/22/2014						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Rifaximin	Tablets	550 mg	Xifaxan 22554	12/18/2015						
Rifaximin	Tablets	200 mg	Xifaxan 21361	1/28/2019						
Riociguat	Tablets	0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg	Adempas 204819	10/10/2017	3					12/4/2026
Risedronate Sodium	Tablets	5 mg, 30 mg and 35 mg	Actonel 20835	4/23/2004						
Risedronate Sodium*	Tablets	75 mg	Actonel 20835	9/10/2007						
Risedronate Sodium	Tablets	150 mg	Actonel 20835	8/12/2008						
Risedronate Sodium	Delayed-release Tablets	35 mg	Atelvia 22560	6/9/2011						
Risedronate Sodium with Calcium Carbonate *	Tablets	35 mg; 500 mg	Actonel with Calcium	12/18/2007						
Risperidone	Oral Solution	1 mg/mL	Risperdal 20588							
Risperidone	Tablets	0.25 mg, 1 mg, 2 mg, 3 mg and 4 mg	Risperdal 20272							
Risperidone	Orally Disintegrating Tablets	0.25 mg	Risperdal 21444	4/11/2005						
Risperidone	Orally Disintegrating Tablets	0.5 mg, 1 mg and 2 mg	Risperdal 21444							
Risperidone	Orally Disintegrating Tablets	3 mg and 4 mg	Risperdal 21444	3/23/2005						
Ritonavir	Tablets	100 mg	Norvir 22417	12/21/2010	1	Eligible	6/18/2019	1/15/2015	3/20/2018	5/10/2021
Ritonavir	Capsules	100 mg	Norvir	10/31/2012						
Rivastigmine Tartrate	Capsules	1.5 mg, 3 mg, 4.5 mg and 6 mg	Exelon 20823	4/21/2004						
Rivastigmine Tartrate	Oral Solution	2 mg/mL	Exelon 21025	11/5/2004	1	Extinguished	8/27/2019			2/11/2014
Rivastigmine	Transdermal System Extended-release	4.6 mg/24 hr and 9.5 mg/24 hr	Exelon 22083	4/27/2011						
Rivastigmine	Transdermal System Extended-release	13.3 mg/24 hr	Exelon 22083	1/22/2013						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Rivaroxaban	Tablets	2.5 mg	Xarelto 22406	11/19/2018	3					11/13/2024
Rivaroxaban	Tablets	10 mg, 15 mg, and 20 mg	Xarelto 22406	7/1/2015	12					8/28/2024
Rizatriptan Benzoate	Tablets	5 mg and 10 mg	Maxalt 20864	9/2/2004						
Rizatriptan Benzoate	Orally Disintegrating Tablets	5 mg and 10 mg	Maxalt-MLT 20865	2/17/2006						
Rofecoxib	Tablets	12.5 mg, 25 mg and 50 mg	Vioxx 21052							
Roflumilast	Tablets	500 mcg	Daliresp 22522	3/2/2015	7	Eligible	6/18/2019	7/13/2018		3/8/2024
Roflumilast	Tablets	250 mcg	Daliresp 22522	1/25/2019	1					3/8/2024
Romidepsin	Injection	10 mg/vial	Istodax 22393	11/5/2013						
Ropinirole Hydrochloride	Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	Requip 20658	12/22/2004						
Ropinirole Hydrochloride	Tablets	3 mg, 4 mg and 5 mg	Requip 20658	2/4/2005						
Ropinirole Hydrochloride	Extended-release Tablets	2 mg	Requip XL 22008	10/14/2008						
Ropinirole Hydrochloride	Extended-release Tablets	4 mg	Requip XL 22008	10/31/2008						
Ropinirole Hydrochloride	Extended-release Tablets	6 mg	Requip XL 22008	7/14/2009						
Ropinirole Hydrochloride	Extended-release Tablets	8 mg	Requip XL 22008	11/3/2008						
Ropinirole Hydrochloride*	Extended-release Tablets	3 mg	Requip XL 22008	1/8/2009						
Ropinirole Hydrochloride	Extended-release Tablets	12 mg	Requip XL 22008	2/5/2009						
Ropivacaine Hydrochloride	Injection	2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials	Naropin 20533	11/13/2006						
Ropivacaine Hydrochloride	Injection	2 mg/mL, 100 mL	Naropin 20533	1/30/2015						
Ropivacaine Hydrochloride	Injection	2 mg/mL, 200 mL	Naropin 20533	9/3/2015	1	Extinguished	6/18/2019	3/16/2018		11/28/2026

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Rosiglitazone Maleate	Tablets	2 mg, 4 mg and 8 mg	Avandia 21071							
Rosiglitazone Maleate and Metformin Hydrochloride	Tablets	1 mg/ 500 mg, 2 mg/ 500mg 4 mg/ 500 mg 2 mg/ 1000 mg 4 mg/ 1000 mg	Avandamet 21410	10/22/2004						
Rosuvastatin Calcium	Tablets	5 mg, 10 mg, 20 mg and 40 mg	Crestor 21366	8/13/2007	9	Non-Forfeiture	8/27/2019	4/29/2016	5/2/2016	8/4/2020
Rotigotine	Extended-release Transdermal Film	1 mg/24 hr 2 mg/24 hr 3 mg/24 hr 4 mg/24 hr 6 mg/24 hr 8 mg/24 hr	Neupro 21829	11/26/2013						
Rufinamide	Tablets	100 mg, 200 mg and 400 mg	Banzel 21911	11/14/2012						
Rufinamide	Oral Suspension	40 mg/mL	Banzel 201367	6/16/2014	1	Extinguished				11/14/2022
Ruxolitinib	Tablets	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	Jakafi 202192	12/17/2015						
Sacubitril and Valsartan New	Tablets	24 mg/26 mg, 49 mg/51 mg 97 mg/103 mg	Entresto 207620	7/8/2019	20					5/27/2027
Sapropterin Dihydrochloride	Tablets	100 mg	Kuvan 22181	6/5/2014						
Sapropterin Dihydrochloride	Powder for Oral Solution	100 mg per packet	Kuvan 205065	11/9/2015	1	Deferred	8/27/2019	8/20/2019		5/17/2025
Sapropterin Dihydrochloride	Powder for Oral Solution	500 mg per packet	Kuvan 205065	2/23/2017	1					11/1/2032
Saxagliptin Hydrochloride	Tablets	2.5 mg and 5 mg	Onglyza 22350	7/31/2013						
Saxagliptin Hydrochloride and Metformin Hydrochloride	Extended-release Tablets	5 mg/500 mg 2.5 mg/1000 mg 5 mg/1000 mg	Kombiglyze XR 200678	7/31/2013						
Sertraline Hydrochloride	Oral Concentrate	20 mg/mL	Zoloft 20990	12/9/2003	1	Eligible	8/27/2019	6/30/2006	8/7/2007	10/11/2019

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Sertraline Hydrochloride	Tablets	25 mg, 50 mg and 100 mg	Zoloft 19839							
Sertraline Hydrochloride	Tablets	150 mg and 200 mg	Zoloft 19839	11/9/2005						
Sevelamer Carbonate *	Powder for Oral Suspension	0.8 g/packet and 2.4 g/packet	Renvela 22318	12/30/2009	1	Extinguished	8/27/2019			9/16/2014
Sevelamer Carbonate	Tablets	800 mg	Renvela 22127	12/4/2008	1	Extinguished	8/27/2019	10/23/2017	4/16/2014	9/16/2014
Sevelamer Hydrochloride	Tablets	400 mg and 800 mg	Renagel 21179	5/22/2008	1	Extinguished	7/30/2019			10/18/2020
Sevoflurane	Inhalation	100%, 250 mL	Ultane 20478							
Sibutramine Hydrochloride	Capsules	10 mg and 15 mg	Meridia 20632	8/14/2009						
Sildenafil Citrate	Tablets	25 mg and 50 mg	Viagra 20895	11/19/2004						
Sildenafil Citrate	Tablets	100 mg	Viagra 20895	10/25/2004						
Silodosin	Capsules	4 mg and 8 mg	Rapaflo 22206	10/9/2012						
Silver Sulfadiazine	Cream	1%	Silvadene 17381							
Simvastatin	Tablets	5 mg, 10 mg, 20 mg, 40 mg and 80 mg	Zocor 19766							
Sirolimus	Tablets	0.5 mg	Rapamune 21110	8/25/2010						
Sirolimus*	Tablets	1 mg and 2 mg	Rapamune 21110	12/17/2009						
Sitagliptin Phosphate	Tablets	25 mg, 50 mg and 100 mg	Januvia 21995	10/18/2010						
Sitagliptin Phosphate and Metformin Hydrochloride	Tablets	50 mg/500 mg and 50 mg/1000 mg	Janumet 22044	10/18/2010						
Sitagliptin Phosphate and Metformin Hydrochloride	Extended-release Tablets	50 mg/500 mg and 50 mg/1000 mg	Janumet XR 202270	3/16/2012						
Sitagliptin Phosphate and Metformin Hydrochloride	Extended-release Tablets	100 mg/1000 mg	Janumet XR 202270	10/22/2012						
Sitagliptin Phosphate and Simvastatin	Tablets	100 mg/10 mg and 100 mg/40 mg	Juvisync 21995	6/19/2012						
Sitagliptin Phosphate and Simvastatin	Tablets	100 mg/20 mg	Juvisync 21995	6/25/2012						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Sitagliptin Phosphate and Simvastatin	Tablets	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	Juvisync 21995	11/6/2012						
Sodium Phosphate Monobasic Monohydrate and Sodium Phosphate Dibasic Anhydrous, USP	Tablets	1.102 g and 0.398 g	Osmoprep 21892	4/9/2008						
Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid	Oral Solution	10 mg, 3.5 g, and 12 g	Prepopik 202535	5/21/2014	1	Extinguished	8/13/2019			10/10/2028
Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid	Oral Solution	10 mg, 3.5 g, and 12 g	Clenpiq 209589	2/11/2019	1					6/26/2034
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate	Oral Solution	17.5 g/3.13 g/1.6 g	Suprep Bowel Prep Kit 22372	11/8/2010						
Sodium Oxybate	Oral Solution	500 mg/mL	Xyrem 21196	7/8/2010	1	Eligible	7/2/2019	1/17/2017		6/16/2024
Solifenacin Succinate	Tablets	5 mg and 10 mg	Vesicare 21518	4/8/2009						
Sofosbuvir	Tablets	400 mg	Sovaldi 204671	12/6/2017						
Sorafenib Tosylate	Tablets	200 mg	Nexavar 21923	2/28/2014	1					2/11/2023
Sumatriptan Succinate	Injection	6 mg/0.5 mL, 0.5 mL vials	Imitrex	10/25/2004						
Sumatriptan Succinate*	Injection	6 mg/0.5 mL, 0.5 mL (prefilled syringes)	Imitrex	5/9/2006						
Sumatriptan Succinate	Tablets	25 mg, 50 mg and 100 mg	Imitrex 20132							
Sunitinib Malate	Capsules	12.5 mg, 25 mg, 37.5 mg and 50 mg	Sutent 21938	1/26/2010						
Tacrolimus	Ointment	0.03%	Protopic 50777	11/22/2010						
Tacrolimus	Ointment	0.10%	Protopic 50777	9/9/2010						
Tacrolimus	Extended-release Capsules	0.5 mg, 1 mg, and 5 mg	Astagraf XL 204096	9/24/2013						
Tadalafil	Tablets	2.5 mg	Cialis 21368	10/14/2008	1	Eligible	6/18/2019	5/22/2018	9/27/2018	11/19/2020

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Tadalafil	Tablets	5 mg, 10 mg and 20 mg	Cialis 21368	11/21/2007	1	Eligible	6/18/2019	5/22/2018	9/27/2018	11/19/2020
Tadalafil	Tablets	20 mg	Adcirca 22332	10/15/2009	1	Eligible	6/18/2019	8/3/2018	8/8/2018	4/26/2020
Taf luprost	Ophthalmic Solution	0.0015%	Zioptan 202514	2/10/2016						
Tamoxifen Citrate	Tablets	10 mg and 20 mg	Nolvadex 17970							
Tamsulosin Hydrochloride	Capsules	0.4 mg	Flomax 20579	12/20/2004						
Tapentadol Hydrochloride	Tablets	50 mg, 75 mg, and 100 mg	Nucynta 22304	11/20/2012						
Tapentadol Hydrochloride	Extended-release Tablets	50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	Nucynta ER 200533	11/20/2012						
Tapentadol	Oral Solution	20 mg/mL	Nucynta 203794	12/20/2013						
Tasimelteon	Capsules	20 mg	Hetlioz 205677	1/31/2018						
Tavaborole	Topical Solution	5%	Kerydin 204427	7/9/2018						
Teduglutide	Injection	5 mg/vial	Gattex Kit 203411	12/21/2016						
Telmisartan	Tablets	20 mg, 40 mg and 80 mg	Micardis 20850	12/26/2006						
Telmisartan and Hydrochlorothiazide	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg	Micardis HCT 21162	12/31/2008						
Temazepam	Capsules	7.5 mg	Restoril 18163	11/01/2006						
Temozolomide	Capsules	5 mg, 20 mg, 100 mg and 250 mg	Temodar 21029	3/20/2007						
Temozolomide	Capsules	140 mg and 180 mg	Temodar 21029	3/24/2008						
Temsirolimus*	Injection	25 mg/mL, 1.8 mL vial	Torisel 22088	5/25/2011						
Tenofovir Disoproxil Fumarate	Tablets	300 mg	Viread 21356	1/26/2010	1	Eligible	6/18/2019	3/18/2015	12/15/2017	1/25/2018
Tenofovir Disoproxil Fumarate	Tablets	150 mg, 200 mg, and 250 mg	Viread 21356	5/17/2012	1	Extinguished	6/18/2019			1/25/2018
Terazosin Hydrochloride	Capsules	1 mg, 2 mg, 5 mg and 10 mg	Hytrin 20347							

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Terazosin Hydrochloride	Tablets	1 mg, 2 mg, 5 mg and 10 mg	Hytrin 19057							
Terbinafine Hydrochloride	Tablets	250 mg	Lamisil 20539							
Terfenadine	Tablets	60 mg	Seldane							
Teriflunomide	Tablets	7 mg and 14 mg	Aubagio 202992	9/12/2016	21	Eligible	6/18/2019	7/27/2018		2/4/2034
Teriparatide	Injection	250 mcg/mL, 2.4 mL prefilled Pen	Forteo 21318	7/27/2015	1					3/25/2025
Testosterone	Gel	1%	Androgel							
Testosterone *	Gel	1%	Testim 21454	8/21/2008						
Testosterone	Gel	1% (pump)	Androgel	12/19/2008						
Testosterone	Gel	1.62% (pump)	Androgel	4/6/2012	1	Eligible		8/4/2015	10/12/2018	8/30/2020
Testosterone	Gel	1.62% (1.25 g and 2.5 g packets)	Androgel	6/19/2013						
Testosterone	Gel	10 mg/actuation	Fortesta 21463	8/14/2012						
Testosterone	Topical Solution	30 mg/1.5 mL	Axiron 22504	1/29/2013						
Testosterone Undecanoate	Injection	250 mg/mL	Aveed 22219	6/11/2014						
Thalidomide	Capsules	50 mg and 100 mg	Thalomid 20785	12/18/2006	1	Extinguished	8/13/2019			10/23/2020
Thalidomide	Capsules	200 mg	Thalomid 20785	9/25/2006	1	Extinguished	8/13/2019			10/23/2020
Thalidomide	Capsules	150 mg	Thalomid 20785	2/3/2014	1					10/23/2020
Tiagabine Hydrochloride	Tablets	2 mg and 4 mg	Gabitril 20646	2/1/2005						
Tiagabine Hydrochloride	Tablets	12 mg and 16 mg	Gabitril 20646	1/24/2014						
Ticagrelor	Tablets	90 mg	Brilinta 22433	7/20/2015						
Ticagrelor	Tablets	60 mg	Brilinta 22433	9/30/2015	1	Eligible	8/13/2019	9/4/2018		4/17/2030
Ticlopidine Hydrochloride	Tablets	250 mg	Ticlid							
Tigecycline	For Injection	50 mg per vial	Tygacil	6/15/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Timolol Maleate	Ophthalmic Solution	0.25% and 0.5%	Timoptic							
Timolol Maleate	Ophthalmic Solution	0.5%	Istalol 21516	10/19/2012						
Tiotropium Bromide	Inhalation Powder Capsules	18 mcg	Spiriva 21395	5/11/2018						
Tizanidine Hydrochloride	Capsules	2 mg, 4 mg and 6 mg	Zanaflex 21447	8/10/2007						
Tobramycin	Inhalation Solution	300 mg/5 mL	Tobi 50753	6/29/2009						
Tobramycin	Inhalation Solution	300 mg/4 mL	Bethkis 201820	8/31/2017	1	Eligible	7/2/2019	6/26/2019		9/22/2022
Tofacitinib	Tablets	5 mg	Xeljanz 203214	11/7/2016	3					12/8/2025
Tofacitinib	Tablets	10 mg	Xeljanz 203214	7/24/2019	1					12/8/2025
Tofacitinib	Extended-release Tablets	11 mg	Xeljanz XR 208246	11/7/2016						
Tolterodine Tartrate	Extended-release Capsules	2 mg and 4 mg	Detrol LA 21228	7/30/2007						
Tolterodine Tartrate*	Tablets	1 mg and 2 mg	Detrol 20771							
Tolvaptan	Tablets	30mg	Samsca 22275	9/23/2013						
Tolvaptan	Tablets	15 mg	Samsca 22275	10/10/2013						
Tolvaptan	Tablets	60 mg	Samsca 22275	3/26/2018						
Topiramate	Capsules	15 mg and 25 mg	Topamax Sprinkle 20844	9/7/2005						
Topiramate	Tablets	25 mg, 100 mg and 200 mg	Topamax 20505	12/26/2001						
Topiramate	Tablets	50 mg	Topamax 20505	9/8/2005						
Topiramate	Extended-release Capsules	25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	Qudexy XR 205122	12/24/2015	1	Non-Forfeiture	8/27/2019			3/19/2033
Topiramate	Extended-release Capsules	200 mg	Trokendi XR 201635	4/3/2014						
Topiramate	Extended-release Capsules	25 mg, 50 mg, and 100 mg	Trokendi XR 201635	5/12/2014						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Torseamide	Tablets	5 mg, 10 mg, 20 mg, and 100 mg	Demadex 20136							
Tramadol Hydrochloride	Tablets	50 mg	Ultram 20281							
Tramadol Hydrochloride	Extended-release Tablets	100 mg	Ultram ER 21692	1/8/2007						
Tramadol Hydrochloride	Extended-release Tablets	200 mg	Ultram ER 21692	3/28/2007						
Tramadol Hydrochloride	Extended-release Tablets	300 mg	Ultram ER 21692	9/25/2007						
Tramadol Hydrochloride	Extended-release Tablets	100 mg, 200 mg and 300 mg	Ryzolt 21745	6/18/2009						
Trandolapril	Tablets	1 mg, 2 mg and 4 mg	Mavik 20528	10/4/2004						
Trandolapril and Verapamil Hydrochloride	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	Tarka 20591	11/9/2007						
Trandolapril and Verapamil Hydrochloride	Extended-release Tablets	1 mg/240 mg	Tarka 20591	2/20/2008						
Trandolapril and Verapamil Hydrochloride	Extended-release Tablets	4 mg/ 240 mg	Tarka 20591	7/24/2007						
Tranexamic Acid	Tablets	650 mg	Lysteda 22430	5/24/2011						
Travoprost	Ophthalmic Solution	0.003%	Izba 204822	12/30/2015	1					10/10/2029
Travoprost	Ophthalmic Solution	0.004%	Travatan 21257	11/28/2008						
Travoprost (Preserved)	Ophthalmic Solution	0.004%	Travatan Z 21994	2/19/2009	1	Extinguished	8/13/2019			12/2/2014
Trazodone Hydrochloride	Tablets	150 mg	Desyrel 18207							
Trazodone Hydrochloride	Extended-release Tablets	150 mg and 300 mg	Olepro 22411	10/18/2010						
Treprostinil Sodium	Injection	10 mg/mL, 20 mL vial	Remodulin 21272	12/2/2011	1	Eligible	6/18/2019	11/30/2017	3/25/2019	3/29/2029
Treprostinil Sodium	Injection	1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial	Remodulin 21272	12/7/2012	1	Eligible	6/18/2019	11/30/2017	3/25/2019	3/29/2029
Treprostinil Sodium	Inhalation Solution	0.6 mg/mL, 2.9 mL ampules	Tyvaso 22387	4/13/2015	1					12/15/2028

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Treprostinil	Extended-release Tablets	2.5 mg	Orenitram 203496	12/24/2015	1					1/22/2031
Treprostinil	Extended-release Tablets	0.25 mg and 1 mg	Orenitram 203496	5/19/2016	1					1/22/2031
Tretinoin	Cream	0.025%, 0.05% and 0.1%	Retin-A							
Tretinoin	Gel	0.025%	Retin-A 17579							
Tretinoin	Gel	0.04%	Retin-A Micro 20475	12/20/2010						
Tretinoin	Gel	0.1%	Retin-A Micro 20475	7/8/2010						
Triamcinolone Acetonide	Nasal Spray	0.055 mg/Spray	Nasacort AQ	12/29/2005						
Triamterene/ Hydrochlorothiazide	Tablets	37.5 mg/25 mg and 75 mg/50 mg	Maxzide 19129							
Trospium Chloride	Extended-release Capsules	60 mg	Sanctura XR 22103	3/2/2009						
Ulipristal Acetate	Tablets	30 mg	Ella 22474	8/13/2014						
Unoprostone Isopropyl*	Ophthalmic Solution	0.15%	Rescula 21214	5/12/2014						
Valacyclovir Hydrochloride	Tablets	500 mg and 1000 mg	Valtrex 20487							
Valganciclovir Hydrochloride	for Oral Solution	50 mg/mL	Valcyte 22257	3/21/2011						
Valganciclovir Hydrochloride	Tablets	450 mg	Valcyte 21304	12/27/2005						
Valsartan	Tablets	40 mg, 80 mg, 160 mg and 320 mg	Diovan 21283	12/28/2004						
Valsartan and Hydrochlorothiazide	Tablets	80 mg/12.5 mg 160 mg/12.5 mg 160 mg/25 mg	Diovan HCT 20818	12/2/2005						
Valsartan and Hydrochlorothiazide	Tablets	320 mg/12.5 mg and 320 mg/25 mg	Diovan HCT 20818	2/7/2007						
Vardenafil Hydrochloride	Tablets	2.5 mg	Levitra 21400	9/4/2009						
Vardenafil Hydrochloride	Tablets	5 mg and 10 mg	Levitra 21400	7/10/2009						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Vardenafil Hydrochloride	Tablets	20 mg	Levitra 21400	3/5/2009						
Vardenafil Hydrochloride	Orally Disintegrating Tablets	10 mg	Staxyn 200179	12/22/2011	1	Extinguished Eligible	6/18/2019 6/18/2019	4/23/2015		10/31/2018
Varenicline Tartrate	Tablets	0.5 mg and 1 mg	Chantix 21928	5/10/2010						
Vasopressin	Injection	20 units/mL, 1 mL	Vasostriect 204485	3/23/2018						
Vasopressin	Injection	20 units/mL, 10 mL	Vasostriect 204485	6/29/2018						
Vecuronium Bromide	For Injection	10 mg/vial and 20 mg/vial	Norcuron 18776							
Venlafaxine Hydrochloride	Tablets	25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg	Effexor 20151	11/03/2005						
Venlafaxine Hydrochloride	Extended-release Tablets	37.5 mg, 75 mg and 150 mg	Effexor XR 20699	5/3/2007						
Venlafaxine Hydrochloride	Extended-release Tablets	37.5 mg, 75 mg and 150 mg	Venlafaxine Hydrochloride 22104	2/12/2009						
Venlafaxine Hydrochloride	Extended-release Tablets	225 mg	Venlafaxine Hydrochloride 22104	1/10/2011						
Verapamil Hydrochloride	Extended-release Capsules	100 mg and 200 mg	Verelan PM 20943	7/20/2006						
Verapamil Hydrochloride	Extended-release Capsules	120 mg, 180 mg and 240 mg	Verelan SR							
Verapamil Hydrochloride	Extended-release Tablets	180 mg	Isoptin SR							
Verapamil Hydrochloride	Extended-release Tablets	240 mg	Covera HS 20552							
Verapamil Hydrochloride	Extended-release Capsules	300 mg	Verelan PM 20943	5/19/2006						
Vilazodone Hydrochloride	Tablets	10 mg, 20 mg, and 40 mg	VIIBRYD 22567	1/21/2015						
Vincristine Sulfate	Injection	1 mg/mL, 1 mL, 2 mL and 5 mL vials	Oncovin 14103							
Voriconazole	For Injection	200 mg/vial	Vfend 21267	9/12/2008						

Paragraph IV Patent Certifications
September 23, 2019

DRUG NAME	DOSAGE FORM	STRENGTH	RLD/NDA	DATE OF SUBMISSION	NUMBER OF ANDAs SUBMITTED	180-DAY STATUS	180-DAY DECISION POSTING DATE	DATE OF FIRST APPLICANT APPROVAL	DATE OF FIRST COMMERCIAL MARKETING BY FTF	EXPIRATION DATE OF LAST QUALIFYING PATENT
Voriconazole	Oral Suspension	40 mg/mL	Vfend 21630	10/8/2010						
Voriconazole	Tablets	50 mg and 200 mg	Vfend 21266	4/14/2008						
Vortioxetine	Tablets	5 mg, 10 mg, 15 mg and 20 mg	Trintellix 204447	10/2/2017	17					6/30/2031
Zafirlukast	Tablets	10 mg and 20 mg	Accolate 20547	2/29/2008						
Zaleplon	Capsules	5 mg and 10 mg	Sonata 20859	6/21/2005						
Zidovudine	Capsules	100 mg	Retrovir 19665							
Ziprasidone Hydrochloride	Capsules	20 mg, 40 mg, 60 mg and 80 mg	Geodon 20825	2/7/2005						
Zoledronic Acid*	Injection	0.05 mg/mL, 100 mL vial	Reclast 21817	8/29/2008						
Zoledronic Acid*	Injection	0.8 mg (base) /mL	Zometa 21223	6/11/2008						
Zoledronic Acid *	Injection	4 mg/100 mL, 100 mL vial	Zometa 21223	1/31/2012						
Zolmitriptan	Nasal Spray	2.5 mg/spray	Zomig 21450	6/9/2016						
Zolmitriptan	Nasal Spray	5 mg/spray	Zomig 21450	11/14/2013						
Zolpidem Tartrate	Extended-release Tablets	6.25 mg	Ambien CR 21774	2/24/2006						
Zolpidem Tartrate	Extended-release Tablets	12.5 mg	Ambien CR 21774	1/19/2006						
Zolpidem Tartrate	Sublingual Tablets	5 mg and 10 mg	Edluar 21997	4/29/2010						
Zolpidem Tartrate	Sublingual Tablets	1.75 mg and 3.5 mg	Intermezzo 22328	4/10/2012						
* ANDA withdrawn or exclusivity relinquished										